Check for updates

OPEN ACCESS

EDITED BY Peter Swaan, University of Florida, United States

REVIEWED BY

Franciska Erdő, Pázmány Péter Catholic University, Hungary Rania Harati, University of Sharjah, United Arab Emirates

*CORRESPONDENCE Ping Zhang, ⊠ 1fy1997011@xxmu.edu.cn

Ming-Feng You, youmingfeng1993@163.com

[†]These authors have contributed equally to this work

RECEIVED 24 January 2025 ACCEPTED 31 March 2025 PUBLISHED 16 April 2025

CITATION

Zhang C-L, Ma J-J, Li X, Yan H-Q, Gui Y-K, Yan Z-X, You M-F and Zhang P (2025) The role of transcytosis in the blood-retina barrier: from pathophysiological functions to drug delivery. *Front. Pharmacol.* 16:1565382. doi: 10.3389/fphar.2025.1565382

COPYRIGHT

© 2025 Zhang, Ma, Li, Yan, Gui, Yan, You and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The role of transcytosis in the blood-retina barrier: from pathophysiological functions to drug delivery

Chun-Lin Zhang^{1†}, Jing-Jie Ma^{2†}, Xiang Li^{1†}, Hai-Qing Yan¹, Yong-Kun Gui¹, Zhi-Xin Yan¹, Ming-Feng You³* and Ping Zhang¹*

¹Department of Neurology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China, ²Department of Audit, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China, ³Department of Neurology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China

The blood-retina barrier (BRB) serves as a critical interface that separates the retina from the circulatory system, playing an essential role in preserving the homeostasis of the microenvironment within the retina. Specialized tight junctions and limited vesicle trafficking restrict paracellular and transcellular transport, respectively, thereby maintaining BRB barrier properties. Additionally, transcytosis of macromolecules through retinal vascular endothelial cells constitutes a primary mechanism for transporting substances from the vascular compartment into the surrounding tissue. This review summarizes the fundamental aspects of transcytosis including its function in the healthy retina, the biochemical properties of transcytosis, and the methodologies used to study this process. Furthermore, we discuss the current understanding of transcytosis in the context of pathological BRB breakdown and present recent findings that highlight significant advances in drug delivery to the retina based on transcytosis.

KEYWORDS

transcytosis, blood-retina barrier, barrier function, vascular leakage, drug delivery

1 Introduction

The retina, an extension of the central nervous system (CNS), plays a crucial role in transforming the image projected on the surface of retina into nerve impulses, facilitating the process of visual perception. The functional retina relies on a stable homeostatic neurovascular microenvironment that facilitates the effective and efficient transportation of oxygen and nutrient from the blood, expels metabolic wastes and protects from pathogens and blood-borne toxins. Previous studies indicate that the strict regulation of solutes, fluids, and cells crossing the BRB is accomplished through two well-defined cell junctions: adherens junctions (AJs) and tight junctions (TJs) (Campbell and Humphries, 2012). Continuous expression of these junction proteins along the basal or apical perimeter of cells establishes a characteristic sealant ring, which restricts the substance exchange through the paracellular pathway (Peng et al., 2003). Besides specialized tight junction complexes, retinal endothelial cells have another property that is essential for their barrier function: a low rate of transcytosis for limiting transcellular transport. The role of TJs and AJs in retinal vascular barrier function is well studied, while the role of endothelial transcytosis in the permeability of the BRB has recently been identified (Ben-Zvi et al., 2014; Knowland et al.,

2014; Greene and Campbell, 2016). The breakdown of the BRB especially is a hallmark of numerous retinal degenerative diseases, including diabetic retinopathy (DR), cystoid macular edema, age-related macular degeneration (AMD), and glaucoma (Cunha-Vaz et al., 2011). Recent researches have highlighted the significant contribution of enhanced endothelial transcytosis to the development of retinal edema (Klaassen et al., 2013; Wang et al., 2020; Zhang et al., 2021).

Transcytosis, also known as transcellular vesicular transport, refers to the intracellular transportation of large molecules (>10 kDa) within vesicles through endothelial cells or epithelial cells (Tuma and Hubbard, 2003; Mehta and Malik, 2006; Garcia-Castillo et al., 2017; Fung et al., 2018). This process has been observed in multiple organs such as the lung, brain, intestine, heart, and retina (Bendayan and Rasio, 1996; Oh et al., 2007; Zhou et al., 2015; Andreone et al., 2017; Chow and Gu, 2017). Multiple macromolecular cargo is conveyed through transcytosis, including low-density lipoproteins, albumin, immunoglobulins, lipids, and insulin (Lee and Klip, 2016; Li et al., 2017; Huang et al., 2019; Raheel et al., 2019; Stapleton et al., 2019). Researches about transcytosis in the CNS barrier function mainly focus on the BBB, while the studies about transcytosis in the BRB are relatively lagging behind. At 1986, E Essner et al. studied the surfaceassociated vesicles in retinal vessels by intravitreal injection of lactoperoxidase or peroxidase (Essner et al., 1986). Their preliminary study indicated that the vesicles were located along the abluminal surface of the vascular endothelial cells. Gregory W Thomas et al. found that 5% human serum albumin reduced transcytosis in human retinal endothelial cells (HREC), which may affect HREC permeability (Thomas et al., 2016). The advancement of electron microscopy technology has significantly accelerated the investigation of the ultra-microstructure of transcellular vesicles in retinal vascular endothelial cells. Leakage from immature retinal vessels occurs exclusively through transcytosis, despite the establishment of functional tight junctions when the vessels first grow into the CNS (Chow and Gu, 2017). The spatio-temporal regulation of transcytosis is crucial for the development of a functional BRB, and major facilitator superfamily domain containing 2a (Mfsd2a) is critical in inhibiting transcytosis at the BRB (Chow and Gu, 2017).

Recent studies have revealed the diverse functions of transcytosis in the BRB. In this review, we summarize the function of transcytosis in the healthy retina, offer a concise overview of the biochemical properties of transcytosis and the methodologies used to study this process. We then discuss the role of transcytosis in pathological BRB breakdown, and strategies for delivering drugs to the retina that leverage transcytosis mechanisms.

2 Transcytosis in healthy BRB

2.1 Endothelial transcytosis as a primary mechanism of transcellular transport across the BRB

Microvascular endothelial cells in the BRB exhibit a specialized barrier property distinct from that of peripheral endothelium. The inner BRB consists of endothelial cells anchored on the basement membrane, covered by Muller cells. These vascular components, together with pericytes, exert regulatory control over retinal endothelial cell function and inner BRB integrity. The outer BRB is composed of retinal pigment epithelium dells, which modulates the transport between the choroidal capillaries and the retina (Figure 1). Microvascular endothelial cells in the BRB exhibit a specialized barrier property distinct from that of peripheral endothelial cells (RMECs) is established through the continuous arrangement of intercellular tight junctions and the maintenance of extremely low rates of transcytosis, which together regulate both paracellular transport and transcellular transport of substances across the BRB on physiological conditions. While previous studies have extensively reviewed paracellular transport in the BRB, this paper will concentrate on transcellular transport in the BRB.

Energy-dependent membrane transporters and vesicular transport mechanisms play crucial roles in regulating the precise movement of solutes and fluids across the BRB. Energy-dependent transcellular transport across RMECs is categorized into five main groups: ion transport, active efflux transport, carrier-mediated transport, caveolae-mediated transport and receptor-mediated transport. For instance, ion transport systems control the flux of ions across RMECs and include several key members such as sodium-potassium-two chloride (Na+-K+-2Cl-) cotransporter (NKCC), sodium pump (Na⁺, K⁺-ATPase), chloride-bicarbonate exchanger, sodium-hydrogen exchanger and sodium-calcium exchanger (Vorbrodt, 1988; O'Donnell et al., 2006; Taylor et al., 2006). The active efflux transport systems mediate the movement of molecules from nervous tissue into the systemic circulation, involving certain solute carrier transporters and adenosine triphosphate-binding cassette efflux transporters, such as organic anion transporter 3, breast cancer resistance protein, and P-glycoprotein (Hermann and Bassetti, 2007; Tajima et al., 2022). The carrier-mediated transport systems are responsible for the influx of certain amino acids, glucose, vitamins and lactate across RMECs (Hawkins et al., 2006; Ohtsuki and Terasaki, 2007; Spector and Johanson, 2007). Caveolae-mediated transport systems are responsible for transporting large molecules like lipoproteins, albumin, and insulin across vascular RMECs. The receptormediated transport systems play a role in transporting large proteins and neuroactive peptides across vascular endothelial cells, such as immunoglobulin G and transferrin (Jefferies et al., 1984; Méresse et al., 1989; Zlokovic, 1995; Deane et al., 2005). It is also noteworthy that there can be overlap between caveolaemediated transport and receptor-mediated transport when the receptors are situated on the caveolae membrane.

Transcytosis refers to the vesicular transport of large molecules between the luminal and abluminal sides of cells and occurs in numerous cell types, such as epithelial cells, endothelial cells, intestinal cells, and neurons (Pulgar, 2018). This biological process encompasses endocytosis (internalization), intracellular vesicular transport, and exocytosis (release) (Pulgar, 2018). Currently, the specific types of vesicles and mechanisms of transcytosis involved in this process remain unclear. However, it is widely accepted that two primary forms of transcytosis exist in endothelial cells of the CNS: receptor-mediated transcytosis and nonselective adsorptive transcytosis. A limited set of peptides and proteins are transported across the BBB via receptor-mediated



transcytosis in the CNS, including iron-transferrin, insulin, and lowdensity lipoprotein (LDL)-cholesterol (Tuma and Hubbard, 2003). Nonselective adsorptive transcytosis mediates the entry of molecules through charged interactions between the cell membrane and the cargo. Various cationic proteins, such as albumin, avidin, and histone, traverse the CNS barrier through this nonselective mechanism (Pardridge et al., 1989; Pardridge and Boado, 1991). Three types of endocytic vesicles have been identified in CNS endothelial cells: caveolae, which is involved in nonselective adsorptive transcytosis and receptor trafficking; clathrin-coated pits, which is primarily responsible for most receptor-mediated transcytosis; and macropinocytotic vesicles (Mayor and Pagano, 2007). Compared with other organs or tissues, fully developed RMECs exhibit a lower transcytosis rate, which is essential for preserving their barrier properties under physiological conditions (Predescu et al., 2004; Anderson, 2008). Transcytosis facilitates the transport of macromolecules from the bloodstream into the retina through specific receptors localized on the vesicular membranes. The low rate of transcytosis in barrier endothelial cells may be attributed to a lower abundance of caveolae within the luminal membrane. In non-barrier endothelial cells, it is achieved by the decreased of albumin receptor expression, caveolin-1, and other associated molecules.

In summary, the active transport of large molecules across endothelial cells in the BRB predominantly occurs through transcellular transport under normal physiological conditions. This process is mediated by mechanisms such as receptormediated and caveolae-mediated transport pathway.

2.2 Mfsd2a and PLVAPs are markers for endothelial transcytosis

Mfsd2a, a member of the major facilitator superfamily, was initially identified as an orphan transporter. The Mfsd2a gene spans approximately 14.3 kb and comprises 13 introns and 14 exons. This gene is highly conserved, with an amino acid sequence that is approximately 85% identical between mice and humans (Eser Ocak et al., 2020). Mfsd2a is selectively expressed in both retinal and cerebral microvessels in the CNS, and plays important roles in both lipid transport and transcytosis (Wong and Silver, 2020). Unlike most other members of the major facilitator superfamily, which transport water-soluble ligands like amino acids and sugars, Mfsd2a is distinct in its ability to transport lipids, particularly lysophosphatidylcholine (LPC) with unsaturated fatty acyl chains (Wong and Silver, 2020). In the brain, Mfsd2a is associated with a reduction in caveolae microdomains within vascular endothelial cells and leads to a significant decrease in transcytosis, independently of TJs (Andreone et al., 2017). In the eye, the spatiotemporal expression of Mfsd2a is closely linked to the

Туре	Mechanism	Structural features	Key molecules	Function/ Characteristics	Examples
Caveolae-mediated transcytosis	Vesicle transport or transient trans-endothelial pores via fusion/fission	Bulb-shaped invaginations (40–80 nm), cholesterol/ sphingolipid-rich, caveolin- 1/cavin-coated, bipolar morphology	Caveolin-1, Cavin-1–4, dynamin	Selective transport of lipids and large molecules; stability depends on cholesterol and sphingolipid- rich membrane domains	Albumin, insulin, LDLs
Clathrin-mediated transcytosis	Clathrin-coated pits form vesicles <i>via</i> AP2/dynamin; HSC70 uncoats vesicles	Triskelion structures (clathrin heavy/light chains), AP2-coated pits, dynamin-mediated fission	Clathrin, AP2, dynamin, PICALM, HSC70, LRP1 receptor	Receptor-mediated endocytosis and transcytosis; selective cargo transport	Insulin receptor, transferrin receptor, Aβ-LRP1 complex, α-synuclein
Macropinocytosis	Actin-driven membrane ruffling forms large irregular vesicles	Irregular vesicles (200–500 nm); plasma membrane ruffling	Actin, MAPK signaling	Nonselective fluid/solute uptake; viral/bacterial entry	<i>E. coli</i> K1, KSHV, HIV-1, non- essential amino acids

LDLs, Low-density lipoproteins; AP2, Adaptor protein 2; PICALM, Phosphatidylinositol binding clathrin-assembly protein; HSC70: Heat shock cognate protein 70; A β , Amyloid-beta peptide; LRP1, Low-density lipoprotein receptor-related protein 1; MAPK, mitogen-activated protein kinase, *E. coli* K1: *Escherichia coli* K1; KSHV, Kaposi's sarcoma-associated herpesvirus; HIV1, Human immunodeficiency virus 1.

gradual suppression of transcytosis, which helps establish a functional BRB (Chow and Gu, 2017). Additionally, Mfsd2a is involved in the transport of docosahexaenoic acid (DHA) in the photoreceptors of retinal pigment epithelial cells (RPEs) in mice (Wong et al., 2016). These findings underscore the importance of Mfsd2a in preserving the barrier function of vascular endothelial cells in both the brain and retina under normal physiological conditions. Additionally, the expression of Mfsd2a can be utilized as an indicator of inhibited transcytosis in the BBB and BRB.

Plasmalemma vesicle-related proteins (PLVAP) is the only discovered molecular component of stomatal diaphragms (SDs) and fenestral diaphragms (FDs) (Stan et al., 1997; Stan et al., 1999). The diaphragms create cap-like structures which connect the opening of caveolae, trans-endothelial channels and fenestrae (Schlingemann et al., 1985; Rothberg et al., 1992; Stan, 2005). PLVAP is a type II integral membrane N-glycosylated glycoprotein with a molecular weight of 55-65 kDa, forming homodimers in situ and binding to heparin at physiological pH (Hnasko et al., 2002; Stan, 2004). The molecular structure of PLVAP consists of a large extracellular domain (380 amino acids), a single span transmembrane domain and a short intracellular domain (27 amino acids) (Stan et al., 1999; Stan, 2005). PLVAP is believed to plays a significant role in regulating vascular permeability and be linked to compromised barrier function in several retinal disorders in various retinal diseases, such as wet AMD, DR and retinopathy of prematurity (ROP) (Wisniewska-Kruk et al., 2014; Wisniewska-Kruk et al., 2016; Nakagami et al., 2019). Therefore, PLVAPs expression is considered as a marker for increased endothelial transcytosis.

3 Biochemical properties of transcytosis

Transcytosis in endothelial cells is regulated by distinct biochemical pathways. Caveolae-mediated transcytosis relies on cholesterol and sphingolipid-rich membrane domains stabilized by caveolin-1 and cavin proteins, enabling selective transport of macromolecules like albumin and LDLs. Clathrin-mediated transcytosis utilizes clathrin triskelions, adaptor proteins, and dynamin for receptor-specific cargo internalization and sorting. Macropinocytosis, driven by actin polymerization and signaling cascades, facilitates nonselective uptake of solutes via large vesicles, critical for nutrient scavenging and pathogen entry. These pathways are regulated by lipid composition, GTPases, and membrane-coating proteins, reflecting their unique biochemical architectures and functional roles in endothelial transport (Table 1 and Figure 2).

3.1 Caveolae-mediated transcytosis

Caveolae are bulb-shaped plasma membrane invaginations and free cytoplasmic vesicles measuring between 40 and 80 nm in size (Parton, 2018). Although initially identified in heart endothelial cells, these vesicles are ubiquitous across various multiple types of cells, such as endothelial cells, adipocytes, fibroblasts, and smooth muscle cells (Palade, 1953; Pilch and Liu, 2011; Chettimada et al., 2015; Marsboom et al., 2017; Filippini et al., 2018). K.R. Peters et al. explored the distribution and structure of endothelial caveolae in cultured endothelial cells using scanning electron microscopy. Caveolae in endothelial cells exhibit flask-shaped invaginations (about 70-90 nm diameter) characterized by a distinctive striped bipolar surface architecture. High-resolution analysis reveals these vesicular structures possess 10-nm-wide meridional ridges separated by linear arrays of dimples. These ridges converge bidirectionally at diametrically opposed poles oriented parallel to the plasma membrane plane, forming a 'bi-polar' morphology distinct from other types of endothelial vesicles. Notably, the plasmalemma's cytoplasmic surface between vesicles exhibited dense reticular organization, composed of irregularly arranged intermediate filaments (about 7-9 nm in diameter) (Peters et al., 1985). Although caveolae are abundant in multiple cells, their number and specific features vary among different cell types. For instance, caveolae density is highest in venular endothelium, reaching up to 1,200 caveolae/µm³ (Simionescu et al., 1974). Furthermore,



endothelial cells possess a larger caveolar neck domain compared to fibroblasts (Richter et al., 2008). The caveolar neck domain recruit actin-binding proteins fission and GTPases, and the larger diameter in neck size may play a significant role in transcytosis. Cholesterol and sphingolipids are the primary components of caveolae, which are essential for their stability and formation (Lajoie and Nabi, 2010; Sengupta, 2012; Krishna and Sengupta, 2019). Depletion of membrane cholesterol disrupts caveolae stability, leading to loss of caveolae (Sengupta, 2012). Additionally, the reduction of phosphatidylserine levels diminishes caveola formation and dynamics, indicating that phospholipids are also functionally important (Hirama et al., 2017).

Caveolins are integral membrane proteins that are vital for various cellular functions, such as lipid trafficking, signal transduction, and endocytosis (Rothberg et al., 1992). Caveolin-1, the first discovered protein in caveolar vesicles in 1992, has significantly advanced our understanding of the function of caveolae, particularly within endothelial cells. This 22 kDa protein features a central hydrophobic domain that forms a hairpin structure within the membrane, with both its hydrophilic carboxyl and amino termini oriented towards the cytoplasm (Tang et al., 2021; Gokani and Bhatt, 2022; Puddu et al., 2023). Caveolin-1 is found in a variety of cell types, such as endothelial cells, adipocytes, and fibroblasts, and its α and β isoform expressed in varying proportions depending on the cell type (Fujimoto et al., 2000; Kogo et al., 2004). For example, lung endothelial cells primarily express the a isoform, while type I alveolar epithelial cells mainly express the β isoform. Notably, caveolin-1 is an essential component for caveolar biogenesis, it is also identified in non-caveolae membrane (Rothberg et al., 1992; Razani et al., 2001). Subsequent studies have indicated that caveolin-1 plays a key role in creating membrane curvature and sequestering cholesterol within caveolar membranes (Hoop et al., 2012). Interestingly, the expression pattern of caveolin-2 resembles that of caveolin-1. However, caveolin-2 is not unnecessary for caveolar formation (Vinten et al., 2005; Hill et al., 2008; Liu et al., 2008). Caveolin 3 is predominantly found in striated muscle and is required for caveolar formation. Interestingly, caveolin-1 alone is sufficient for caveolar morphogenesis, while caveolin-3 works in conjunction with syndapin III to mediate caveolae formation in muscle tissue (Fra et al., 1995; Razani et al., 2002; Murata et al., 2007).

Over the past two decades, researchers have identified four caveolae coat-associated proteins with defined functions, namely, the cavin family (cavin 1-4). These cavins assemble into higherorder hetero-oligomeric structures, which are crucial for the architecture and functionality of caveolae. Cavin-1 (polymerase transcript release factor, PTRF) and cavin-2 (serum deprivation protein response, SDPR) are essential for caveolar formation and abundance, and they are the most extensively studied among these four proteins (Liu and Pilch, 2008; Tkachenko et al., 2012). Cavin-1 not only binds to phosphatidylinositol bisphosphate, but also associates with caveolar membrane through its interaction with phosphatidylserine (Busija et al., 2017). Both phosphatidylserine and phosphatidylinositol bisphosphate are necessary for caveolar formation. Moreover, Cavin-1 indirectly participates in caveolin-1 oligomerization by interacting with caveolin-1 in a 4:1 ratio (Ludwig et al., 2013). Cavin-1 knockout mice exhibit reduced caveolae and develop muscle hypertrophy through AKT signaling, as well as cardiac hypertrophy and fibrosis via extracellular regulated protein kinases (ERK) signaling (Taniguchi et al., 2016; Ding et al., 2017). Although cavin-2 is critical for the targeting of cavin-1 to the caveolar coat, its deletion does not have a widespread influence on caveolae throughout the body. For example, cavin-2 knockout reduced endothelial caveolae in the adipose tissue and lung tissue, but does not influence caveolae in the heart endothelium (Hansen et al., 2013). Moreover, cavin-2 affects caveolar membrane curvature, and its overexpression results in caveolae deformation and extensive plasma membrane tubulation (Hansen et al., 2009). In vitro, cavin-2 knockout leads to decreased endothelial cell proliferation, migration, angiogenesis, and nitric oxide production (Boopathy et al., 2017). Cavin-3 (srd-related gene product that binds to c-kinase, SRBC) knockout decreases caveolae density in smooth muscle cells, while having little effect on caveolae abundance in lung endothelial cells, adipocytes, and fibroblasts (Hansen et al., 2013; Liu et al., 2014; Zhu et al., 2017). Lastly, cavin-4 (muscle-restricted coiled-coil protein, MURC) is exclusively expressed in myocytes, and its overexpression increases caveolae abundance in cardiomyocytes in vitro (Ogata et al., 2014).

The hypothesis that caveolae-mediated transcytosis happens via vesicle transport and/or transient trans-endothelial pores formed by the fusion and fission of caveolae is supported by the integration of electron microscopy and cell biology studies (Peters et al., 1985; Ghitescu et al., 1986). Several laboratories have demonstrated the uptake of labeled plasma proteins into caveolar vesicles. Caveolae are typically identified using GFP-tagged caveolin-1 in live imaging studies. Evidence from total internal reflection fluorescence microscopy indicates that GFP-tagged caveolin-1 rapidly internalizes upon exposure to albumin in endothelial cells (Jiang et al., 2016; Zimnicka et al., 2016). Furthermore, the knockout of caveolin-1 in mice leads to decreased albumin internalization and reduced endothelial transcytosis (Schubert et al., 2001). In blood vessels, endothelial cells on the luminal side can transport lipids and proteins from the circulation to the abluminal side and vice versa. Additionally, other studies have confirmed that caveolae can transport insulin, albumin, and low-density lipoproteins (LDLs) (Vasile et al., 1983; Ghitescu et al., 1986; Nistor and Simionescu, 1986; Bendayan and Rasio, 1996). Thus, caveolae serve as the key mediators of transcellular transport within endothelial cells.

Other transient organelles, trans-endothelial channels, and vesicular-vacuolar organelles (VVOs) also play significant roles in fluid and solute permeability. VVOs are present in both tumor endothelium and normal venular endothelium, mediating the exudation of macromolecules in response to factors such as vascular endothelial growth factor (VEGF), serotonin, and histamine (Dvorak et al., 1996; Lin et al., 2008). Evidence from studies involving Caveolin-1 knockout mice indicates that caveolae are not essential for the formation of VVOs, suggesting that these organelles may be independent of caveolar structures (Chang et al., 2009). While VVOs have not been observed in capillaries, multiple studies have shown that the transcytotic transport of proteins with large molecular weight occur within capillary beds. Consequently, the question of whether VVOs are caveolae-independent structures or represent fused caveolar vesicles remains controversial. Additionally, transendothelial channels (TEC) are found in fenestrated endothelium, such as that in the exocrine pancreas, kidney cortex, and duodenal mucosa, but are absent in continuous endothelial cells (Stan, 2007).

3.2 Clathrin-mediated transcytosis

Clathrin is a highly evolutionarily conserved protein composed of a heavy chain with a molecular weight of 180 kDa and a light chain with a molecular weight ranging from 35 to 40 kDa, which together form a dimer. Three such dimers assemble to create the fundamental structural unit known as the triskelion (Kaksonen and Roux, 2018). Clathrinmediated transcytosis is a vital process that facilitates the endocytosis of cargo through clathrin-coated pits and is observed across a range of cell types. Extensive research has identified multiple proteins participating in the initial phase of clathrin-coated vesicle formation at the cellular membrane (Kaksonen and Roux, 2018). For example, the adaptor complex adaptor protein 2 (AP2) promotes the formation of clathrincoated pits consisting of clathrin light chain and heavy chain (Pearse, 1976; Motley et al., 2003). The GTPase dynamin triggers the detachment of pits from the plasma membrane, resulting in the formation of clathrin-coated vesicles (Sweitzer and Hinshaw, 1998). Subsequently, the clathrin coat is disassembled by the ATPase Heat shock cognate protein 70 (HSC70), and the uncoated vesicles then fuse with early endosomes, thereby entering the endosomal sorting pathway (Schlossman et al., 1984). Several receptors, including the insulin receptor and transferrin receptor, were found to experience clathrinmediated endocytosis (Duffy and Pardridge, 1987; Roberts et al., 1993). Hyperinsulinemia has been shown to disrupt the internalization of insulin receptors into brain endothelial cells, impacting the regulation of molecular targets involved in cerebral blood flow (DiLucia et al., 2023). Recent studies have demonstrated that the transport of amyloid-beta peptide (AB) from the brain to the circulation relies on clathrinmediated endocytosis (Deane et al., 2004; Zhao et al., 2015). Mechanistically, AB binds to the low-density lipoprotein receptor-Related Protein 1 (LRP1) receptor located on the abluminal side of the BBB, and the endocytic protein phosphatidylinositol binding clathrin-assembly protein (PICALM) is involved in regulating the clathrin-dependent internalization of the AB-LRP1 complex which leads to the endocytic transport and subsequent clearance of Aβ. Parvez Alam et al. observed significant colocalization of a-synuclein with clathrin, indicating that a-synuclein is internalized in brain endothelial cells via a clathrin-dependent mechanism (Alam et al., 2022). While a-synuclein did not colocalize with caveolin-1, the knockout of caveolin-1 in endothelial cells inhibits luminal to abluminal a-synuclein transcytosis, suggesting an indirect involvement of caveolin-1 in α -synuclein trafficking (Alam et al., 2022).

3.3 Macropinocytosis

Macropinocytosis is a nonselective endocytic pathway initiated by actin polymerization at the cell plasma membrane, which promotes the formation of membrane ruffles (Lim and Gleeson, 2011). These membrane ruffles represent extensions of the plasma membrane, and they may come from the leading edge of cells and then fold back, or originate from the dorsal surface of cells and then form the circular cups (Lim et al., 2015). Ruffles can encapsulate solutes into irregularly shaped vesicles, known as macropinosomes, which vary in size from 200 to 500 nm (Lim and Gleeson, 2011). Following their formation, macropinosomes can undergo homotypic fusion and fission and may also be transported to other organelles within the endosomal system (Wang et al.,



Assessment of transcytosis *in vitro*.HRP in conjunction with a fluorescent substrate (A), Cy3-11 (B), or dextran-1MR (C) are used for the measurement of caveolae-mediated transcytosis, clathrin-mediated transcytosis, and macropinocytosis, respectively. HRP: Horseradish peroxidase, Cy3-Tf: Cyanine 3 labeled transferrin, dextran-TMR: dextran conjugated to tetramethylrhodamine, EC: Endothelial cell, HEK293: Human embryonic kidney 293 cells.

2014). While early studies on macropinocytosis primarily focused on immune cells, such as dendritic cells and macrophages, subsequent research has identified this process in various nonimmune cell types, such as neurons, epithelial cells, endothelial cell, fibroblasts, and cancer cells (West et al., 1989; Ridley et al., 1992; Wennström et al., 1994; Commisso et al., 2013; Holmes et al., 2013).

Macropinocytosis is associated with several biological functions, including cell metabolism, virus infection and gene expression. In human umbilical vein endothelial cells (HUVECs), glutamine deprivation enhances macropinocytosis, promoting the nonessential amino acids uptake and sustaining cell proliferation (Kim et al., 2017). In hCMEC/D3 cells, a type of human brain microvascular endothelial cells (HBMECs), the internalization of neutrophil-derived microvesicles alters the gene expression profile, leading to the dysregulation of genes related to vesicular transport, ubiquitinmediated proteolysis, and tight junctions (Ajikumar et al., 2019). Various pharmacological inhibitors have been employed to elucidate the role of macropinocytosis in the uptake of neutrophil-derived microvesicles. These include cytochalasin D, which inhibits actin polymerization and microfilament formation; dynasore, which disrupts dynamin function; 5-(N-Ethyl-N-isopropyl) amiloride, which inhibits Na+/H+ exchangers crucial for macropinocytosis; genistein, which blocks caveolin-mediated endocytosis; and which inhibits clathrin-mediated monodansylcadaverine, endocytosis (Ajikumar et al., 2019). Additionally, macropinocytosis is also involved in viral entry into endothelial cells. For example, the bacterium Escherichia coli K1 enters HBMECs via micropinocytosis (Loh et al., 2017). Invasion of Kaposi's sarcoma-associated herpesvirus (KSHV) into HUVECs and HBMECs is also via micropinocytosis. KSHV infection significantly elevates the membrane ruffling and uptake of 70 kDa dextran in the above 2 cell types (Raghu et al., 2009). Furthermore, macropinocytosis plays a critical role in the entry of human immunodeficiency virus 1 (HIV-1) into primary HBMECs, a process involving mitogen-activated protein kinase (MAPK) signaling, lipid rafts, and glycosaminoglycans (Liu et al., 2002).

Endothelial cells exhibit low levels of constitutive macropinocytosis under physiological conditions; however, this process can be upregulated in response to growth factors. In porcine aortic endothelial cells, basal membrane ruffling occurs at low levels. Platelet-derived growth factor (PDGF) enhances levels of PI(3,4,5)P3 and stimulates membrane ruffling, a process that requires phosphatidylinositol 3-kinase (PI3K) signaling (Wennström et al., 1994).

4 Methods for investigating transcytosis *in vitro* and *in vivo*

4.1 Assessment of transcytosis in vitro

Transcytosis can be quantified via fluorescence-based assays conducted *in vitro*. In cell cultures, the application of horseradish peroxidase (HRP) in conjunction with a fluorescent substrate, fluorescently labeled transferrin (Cy3-Tf), or dextran conjugated to tetramethylrhodamine (dextran-TMR) allows for the precise measurement of caveolae-mediated transcytosis, clathrinmediated transcytosis, and macropinocytosis events, respectively (Figure 3). These methodologies offer a robust and sensitive approach to elucidate the mechanisms underlying vesiclemediated transport across the endothelial barrier, providing significant insights into the complex processes that govern transcytosis.

HRP-based assay is commonly used to evaluate caveolaemediated transcytosis (Wang et al., 2020; Zhang et al., 2021) (Figure 3). When endothelial cells reach full confluency in the transwell chamber (TEER value around 20 Ω ·cm²), they undergo serum starvation overnight at 37°C prior to the assay. A 2.5 mg/mL solution of HRP was added to the apical compartment of the epithelial layer and cells are incubated at 37°C for 20 min. The chambers are subsequently washed multiple times with precooled phosphate-buffered saline (PBS) to remove any unbound extracellular HRP. Once the washing steps were completed, fresh medium is added to both the upper and lower chambers, and incubation continues for an additional 60 min at 37°C. Following this incubation period, the medium from the lower chamber was collected, and HRP concentration was subsequently analyzed.

The transport of Cy3-Tf can be used to evaluate clathrinmediated transcytosis in endothelial cells (Sade et al., 2014) (Figure 3). Endothelial cells were cultured to full confluency on transwell chamber and subjected to serum starvation overnight at 37° C before the assay began. The cells were then incubated apically with Cy3-Tf for 60 min at 37° C. Following incubation, the chambers were thoroughly washed several times with precooled PBS to remove any unbound extracellular Cy3-Tf. New medium was then added to both the upper and lower chambers, and the incubation continued for 60 min to release the endocytosed Cy3-Tf. The medium from the lower chamber was collected, and the corresponding fluorescence intensity of Cy3-Tf was measured.

Previous studies about assessment of macropinocytosis mainly focused on antigen-presenting cells such as macrophages and dendritic cells. David Liebl et al. reported a modified quantitative protocol to assess the rate and volume of macropinocytosis in human embryonic kidney cells (HEK293) (Figure 3), which could be also be extended to the measurement of micropinocytosis in other adherent cells (Bora et al., 2022). 10,000 MW dextran conjugated to tetramethylrhodamine was chose to measure micropinocytosis. HEK293 cells were cultured on poly-l-lysine-coated coverslips and subjected to serum starvation at least for 16 h before the assay. The cells were then pulsed with 100 μ g/mL dextran–TMR for 5 min. The number of macropinosomes was quantified using automated image analysis. Future research is required to evaluate the practicality of this approach for analyzing endothelial macropinosomes.

4.2 Assessment of transcytosis in vivo

Current *in vivo* assessments of vascular leakage typically utilize colorimetric (such as HRP substrate and Evans Blue dye), fluorescent (dextran and sodium fluorescein), or radioactive tracers to detect extravasation from retinal vessels into adjacent tissues (Saunders et al., 2015). The ideal properties of a tracer for quantifying vascular leakage include inertness and large molecular size, which allow it to permeate damaged vessels and remain restricted within healthy ones. Evans blue dye binds with endogenous albumin to form a large molecule in the circulation after injection through the tail vein or intracardially, which could be visualized by fluorescence microscopy or quantified by spectrophotometric detection (Wu et al., 2020; Honeycutt and O'Brien, 2021; Li et al., 2023). Fluorescein isothiocyanateconjugated dextran (FITC-dextran) and sodium fluorescein are wildly used in the assessment of retinal vascular leakage in vivo or ex vivo (Atkinson et al., 1991; Natarajan et al., 2017; Comin et al., 2021). Usually, 4 to 70 kD FITC-dextran can be selected based on specific experimental requirements. Additionally, FITC-albumin (approximately 68 kDa) serves as an alternative large-sized protein tracer for measuring vascular leakage (Pietra and Johns, 1996; Doggett and Breslin, 2014). Importantly, while these methods effectively detect retinal vascular leakage, they do not differentiate between trans-endothelial transport and paracellular transport. Specific tracers, such as HRP, are often utilized to locate transendothelial vesicles and analyze their ultra-microstructure under electron microscopy (Chow and Gu, 2017; Wang et al., 2020; Zhang et al., 2021).

Notably, vascular leakage assays, such as Evans Blue, FITCdextran and albumin tracers cannot directly distinguish transcytosis from paracellular leakage. However, the methodologies described can indirectly infer transcytosis activity under specific experimental conditions, particularly when combined with complementary approaches, such as tracer size selection, electron microscopy validation and cell-specific pathway inhibition. First, transcytosis is typically associated with the transport of large molecules, while tight junctional dysfunction leads specifically to t the leakage of lowmolecular-weight tracers 1 kDa and below (O'Brown et al., 2019). By comparing leakage of small tracers and large tracers under the same conditions, an increased permeability to large molecules may suggest active transcytosis rather than passive paracellular flux (Cui et al., 2021). Second, HRP tracers combined with ultrastructural analysis can visualize trans-endothelial vesicles and their cargo content. This approach provides direct evidence of transcytosis (Sadeghian et al., 2018). Third, pharmacological or genetic tools can block transcytosis without affecting paracellular junctions. Suppressed leakage of large tracer after such interventions could further support transcytosis involvement (Deffebach et al., 1996). Current methodologies do not fully resolve transcytosisspecific signals. In future work, dual-tracer imaging and endothelial-specific genetic models may help the study of transcytosis.

5 Transcytosis in pathological breakdown of the BRB

5.1 Plasmalemma vesicleassociated proteins

Endothelial cell-specific expression of PLVAP decreases during development and is absent once the functional BRB is established. The lack of PLVAP in barrier endothelial cells is crucial for both the formation and maintenance of the BRB (Daneman et al., 2010; Liebner and Plate, 2010; Umans et al., 2017). PLVAP is significant not only for preserving the fundamental vascular barrier function in particular subsets of vascular endothelial cells but also for contributing to BRB breakdown under pathological conditions, such as DR, AMD and ROP (Schlingemann et al., 1999; Witmer et al., 2002; Wisniewska-Kruk et al., 2016; Nakagami et al., 2019).



FIGURE 4

Transcytosis in pathological breakdown of the BRB. PLVAP, Wnt-Mfsd2a signaling and Dll4-Notch1 signaling are involved in the regulation of transcytosis in pathological breakdown of the BRB. JNJ47965567 inhibits transcytosis through P2X7R blockade-mediated regulation of PLVAP expression. PLVAP: Plasmalemma vesicle-associated proteins, Mfsd2a: Major facilitator superfamily domain containing 2a, Dll4: Delta-like ligand 4, VEGFR2: Vascular endothelial growth factor receptor 2, SOX7: SRY related high mobility group box 7, Wnt: Wingless-related integration site, P2X7R: Purinergic 2X7 receptor, EC: Endothelial cell.

VEGF has been proved to mediate several transcellular transport-associated genes and to increase caveolae-mediated transcytosis in vivo. Wisniewska-Kruk et al. demonstrated that the expression of PLVAP correlates with the loss of BRB properties in retinal capillaries, contributing to retinal vascular permeability in diabetic macular edema (DME). The knockdown of PLVAP reduced VEGF-mediated caveolae formation and the permeability of the BRB in vitro (Wisniewska-Kruk et al., 2016) (Figure 4). Different-sized tracers were utilized to explore the function of PLVAP inhibition in retinal vascular leakage in an in vitro BRB model. Previous studies indicate that larger molecules primarily penetrate the endothelial barrier through the transcellular pathway, while smaller molecules utilize the paracellular pathway. PLVAP inhibition decreased the permeability of 70 kDa tracers mediated by VEGF without affecting the permeability of 766 Da tracers (Wisniewska-Kruk et al., 2012; Wisniewska-Kruk et al., 2016). Furthermore, PLVAP inhibition did not influence VEGF-mediated changes in endothelial junctions (Wisniewska-Kruk et al., 2016). In an oxygen-induced retinopathy (OIR) mouse model, PLVAP inhibition was found to preserve BRB integrity, as indicated by reduced extravasation of 70 kDa fluorescent tracers and findings from fluorescein angiography (Wisniewska-Kruk et al., 2016). Therefore, PLVAP expression serves as a critical modulator of VEGF-induced transcellular transport. Notably, while PLVAP inhibition reduced VEGF-mediated caveolae formation to baseline levels, it did not affect the overall number of basal caveolae (Herrnberger et al., 2012; Wisniewska-Kruk et al., 2016). There was no significant decrease in the basal caveolae number in endothelial cells from PLVAP knockout mice. Although PLVAP inhibition does not regulate

basal caveolae numbers under normal conditions, it undeniably plays a role in pathological vasogenic edema (Herrnberger et al., 2012; Wisniewska-Kruk et al., 2016). Given that vesicular trafficking is a complex biological process involving multiple proteins and molecules, changes in caveolae numbers may not necessarily correlate with alterations in transcytosis. However, the precise molecular mechanism by which PLVAP regulates caveolae formation and modulates cellular barrier function remains incompletely understood. Previous studies have shown that VEGF receptor 2 (VEGFR2) is localized in caveolae and that PLVAP expression is induced in a VEGFR2-dependent manner (Labrecque et al., 2003; Tahir et al., 2009). It is possible that PLVAP modulates VEGFR2 function to regulate caveolae formation and vascular barrier function. Notably, PLVAP has been found to interact with neuropilin-1 (NRP-1), an important co-receptor of VEGFR2 that regulates its surface expression (Keuschnigg et al., 2012; Gelfand et al., 2014). Therefore, PLVAP may influence the function or stability of VEGFR2/NRP-1 complexes, thereby modulating downstream VEGFR2 signaling. Further research is essential to clarify the precise molecular mechanisms involved in these processes. Besides VEGF, several signaling pathways and biological processes have been reported to modulate PLVAP expression, such as angiotensin-2, Norrin/wingless-related integration site (Wnt) signaling, transforming growth factor- β , Notch signaling, shear stress and tumor necrosis factor-a (Wasserman et al., 2002; Liebner et al., 2008; Liebner and Plate, 2010; Bodor et al., 2012; Farber et al., 2018).

Currently, anti-VEGF therapy is the primary treatment for DME. However, repeated intravitreal injections of anti-VEGF agents can lead to retinal fibrosis in DME patients with severe proliferative diabetic retinopathy (PDR) (Van Geest et al., 2012). Moreover, such injections have also been found to increase vascular leakage and induce retinal neurodegeneration in mouse models (Hombrebueno et al., 2015). Long-term anti-VEGF therapy may result in retinal damage, ultimately adversely affecting visual function. А recent study demonstrated that JNJ47965567 preserves BRB integrity through purinergic 2X7 receptor (P2X7R) blockade-mediated regulation of PLVAP expression (Platania et al., 2025). Notably, PLVAP is exclusively expressed in endothelial cells, suggesting that targeting PLVAP expression in retinal and brain endothelial cells potentially inhibit downstream VEGF signaling pathways without compromising neuronal cell survival. Additionally, PLVAP inhibition has been shown to significantly reduce retinal vascular leakage in vivo and protect cellular barrier function in vitro, indicating that anti-PLVAP treatment may represent a safer therapeutic option for DME.

5.2 Wnt-Mfsd2a signaling

Mfsd2a was initially identified as a regulator of BBB formation through the inhibition of transcytosis (Ben-Zvi et al., 2014). Although Mfsd2a knockout mice exhibited functional tight junctions, their BBB remained leaky due to increased transcytosis (Ben-Zvi et al., 2014). Brian Wai Chow et al. study the role of Mfsd2a in BRB function. Mfsd2a knockout resulted in elevated HRP-filled vesicle density in retinal endothelial cells of HRP-injected adult mice, without affecting tight junction integrity. Subsequent studies have shown that the active suppression of transcytosis is a fundamental mechanism regulating BBB function, which is dynamically influenced by various pathophysiological conditions. Our recent study provided direct evidence for the Mfsd2a-mediated regulation of transcytosis in diabetic retinal endothelial cells using the streptozotocin (STZ) model (Zhang et al., 2021). We demonstrated that decreased expression of endothelial Mfsd2a was associated with diabetic retinal vascular leakage. Transmission electron microscopy and HRP-based in vitro transcytosis assays revealed that downregulation of Mfsd2a led to increased endothelial vesicular transcytosis (Figure 4). We investigated four potential vesicle-traffickingrelated proteins (caveolin1, SEC22 Homolog B (Sec22b), Syntaxin7 (STX7), and Slit-Robo Rho GTPase activating protein 2 (Srgp2)) in the STZ model, which have been reported to be regulated by Mfsd2a, and found that Sec22b is essential for endothelial vesicular transcytosis in the STZ model (Zhang et al., 2021). Overexpression of Mfsd2a reduced both type I trans-endothelial vesicles (vesicles forming via endocytosis from the luminal membrane) and type II trans-endothelial vesicles (already formed vesicles transported within the cytoplasm), thereby decreasing diabetic retinal vascular leakage. Furthermore, the combination of Mfsd2a overexpression and oral administration of DHA further reduced the density of type I transendothelial vesicles in the STZ mode (Zhang et al., 2021). Interestingly, another study found that the high dose fish oil treatment (818.2 mg/kg of eicosapentaenoic acid (EPA) and 545.5 mg/kg DHA per day, lasting for 21 days) elevated the expression of Mfsd2a without affecting DHA homeostasis in the retina and retinal pigment epithelium from healthy mice (Jovanović Macura et al., 2022). Another study found that High-dose fish oil

supplementation increased Mfsd2a, and reducing AQP4 expression and AB deposition in retinal vessels of 5xFAD mice (Alzheimer's mouse models), thereby suppressing transcytosis or enhancing lymphatic system function in the retina (Jovanovic Macura et al., 2024). These findings suggest that Mfsd2a expression may vary based on different pathophysiological conditions or DHA dosages, highlighting its critical role in mediating excessive endothelial transcytosis associated with retinal vascular leakage. Zhang et al. demonstrated that dysregulated transcytosis contributes to BRB breakdown in glaucoma pathogenesis. Their study revealed vascular leakage originating from the peripheral veins of the retinal ganglion cell layer, accompanied by significant downregulation of Mfsd2a. Notably, this pathological leakage occurred in the absence of endothelial junction disruption. The stabilization of β-catenin in retinal endothelial cells effectively subsequent prevented both BRB dysfunction and neurodegeneration in the glaucoma murine model (Zhang et al., 2024).

Wang et al. explored the role of Wnt signaling in retinal endothelial cell transcytosis and BRB function in 2 mouse models: low-density lipoprotein receptor-related protein 5 (Wnt co-receptor) knockout (Lrp5^{-/-}) mice and Norrin (Wnt ligand) knockout (Ndp^{y/-}) mice. Both models showed elevated retinal endothelial transcytosis and increased retinal vascular leakage (Wang et al., 2020). Wnt signaling was found to directly regulate the expression of Mfsd2a in a β-catenin-dependent manner, Mfsd2a overexpression inhibited Wnt deficiency-mediated transcytosis in endothelial cells (Figure 4). Additionally, both models displayed elevated caveolin-1 expression and an abundance of caveolar vesicles. Mfsd2a overexpression led to a reduction in caveolin-1 levels, as well as a reduction in type I and type II trans-endothelial vesicles and the density of immunogold-labeled caveolin-1-positive trans-endothelial vesicles in Lrp5^{-/-} mice. The research suggests that Wnt signaling plays a crucial role in mediating Mfsd2a-dependent transcytosis within the vascular endothelium, specifically through a caveolin-1-positive caveolae pathway (Wang et al., 2020). Furthermore, the loss of Apcdd1, which acts as a negative regulator of Wnt signaling, increased the transcriptional activity of endothelial $\beta\mbox{-}catenin,$ leading to delayed vessel pruning and premature BRB formation in the postnatal retina (Mazzoni et al., 2017). In vitro studies on Apcdd1-/- brain endothelial cells revealed an increase in transcytosis and a compromised transcellular barrier, which could be partially reversed by exposure to Wnt3a. Interestingly, there were no notable differences in PLVAP and caveolin-1 protein expression or albumin uptake between Apcdd1 mutant mice and their wild-type littermate controls. The authors hypothesized that the loss of Apcdd1 in brain endothelial cells might promote the maintenance of PLVAP-expressing fenestrae, leading to an increase in albumin uptake. This phenomenon may be attenuated in vivo due to pericyte-derived signals that could reduce PLVAP expression in Apcdd1-/- retinal endothelial cells (Mazzoni et al., 2017).

5.3 Dll4-Notch1 signaling

Delta-like ligand 4 (Dll4) plays a multifaceted role in the development of the vascular system, with its functions in adult

vasculature, particularly in lacteal and cardiac vessels, becoming increasingly recognized (Hellström et al., 2007; Suchting et al., 2007; Bernier-Latmani et al., 2015; Pitulescu et al., 2017; Jabs et al., 2018). Jee Myung Yang et al. investigated Dll4's role in maintaining the integrity of the BRB (Yang et al., 2020). Their study initially examined the function of Dll4 in BRB maintenance in adult mice. A single intravitreal injection of anti-Dll4 antibody caused the extravasation of dextran (4 and 10 kDa) and Evans blue dye in the superficial vascular plexus. Leakage of Evans blue from arteries was detected 3 days post-injection, while leakage in veins and capillaries was observed after 7 days (Yang et al., 2020). By 10 days, Evans blue leakage diminished and became restricted to periarterial regions. Further research indicated that endothelial Dll4-Notch1 signaling is crucial for maintaining retinal barrier integrity by inhibiting transcytosis. Genetic or antibody-mediated inactivation of Dll4 resulted in increased immunostaining of caveolin-1 and PLVAPs in retinal arteries and arterioles, without altering the levels or distribution of VE-cadherin, zonula occludens-1 (ZO-1), claudin-5, or occludin (Figure 4) (Yang et al., 2020). Additionally, inhibition of Notch1 led to the extravasation of tracers and elevated expressions of caveolin-1 and PLVAPs in endothelial cells, while not affecting VE-cadherin and claudin-5 expression. The SRY-box transcription factor 17 (Sox17) serves as an upstream regulator of Dll4; endothelial knockout of Sox17 reduced arterial Dll4 expression and led to tracer extravasation, increased PLVAP and caveolin-1 expression, and a rise in transcellular vesicles in arterial endothelial cells (Yang et al., 2020) (Figure 4). Furthermore, sterol regulatory element-binding protein 1 (SREBP1) mediates Dll4 inhibition-induced transcytosis. The SREBP1 inhibitor fatostatin reduced dextran leakage, the expression of PLVAP, and the formation of transcellular vesicles following the intravitreal injection of anti-Dll4 antibody (Yang et al., 2020). In a model of hypertension-induced retinal edema, the Sox17-Dll4-SREBP1 signaling axis was also implicated in pathological retinal vascular leakage (Yang et al., 2020).

6 Targeting transcytosis for drug delivery across the BRB

The BRB comprises the retinal capillary endothelial cells (RCECs) and the RPEs. RCECs establish the inner blood-retinal barrier, while RPEs establish the outer barrier. Both cell types feature tight junctions that restrict the passage of drugs between the neural retina and the circulating blood. Within the RPEs, specialized transport proteins and vesicles facilitate the exchange of specific active pharmaceuticals between the choroid and the retina. Strategies for drug delivery to the retina typically involve creating complexes between drugs and receptor-targeting entities or directing them to specific transport vesicles.

Previous research has demonstrated that clathrin-mediated endocytosis, caveolae-mediated endocytosis, and macropinocytosis can operate independently or synergistically to mediate drug delivery. For instance, iron delivery to the CNS occurs through the specific binding and intracellular trafficking of transferrin, and the transferrin receptor has been shown to be a key target for retinal drug delivery. Atsushi Imakiire et al. identified a fusion protein, pabinafusp alfa, which consists of iduronate-2-sulfatase and an antihuman transferrin receptor antibody. This fusion protein demonstrated the ability to cross the BRB and effectively reached retinal tissue in a murine model of mucopolysaccharidosis (Imakiire et al., 2023). Rathapon Asasutjarit et al. developed a transferrin-conjugated liposomes containing ganciclovir (Tf-GCV-LPs), which can be administered via intravitreal injection or topical instillation. Tf-GCV-LPs exhibited a negative zeta potential, a particle size of less than 100 nm, and good biosafety in ARPE-19 cells. These liposomes were internalized by ARPE-19 cells through transferrin receptor-mediated endocytosis and exhibited inhibitory activity against cytomegalovirus in infected cells (Asasutjarit et al., 2020). Moreover, functionalizing the surface of dual-functionalized poly (lactide-co-glycolide) nanoparticles with transferrin, a linear arginine-glycine-aspartic acid peptide, or a combination of both enhanced the retinal delivery of nanoparticles following intravenous administration (Singh et al., 2009). These findings support the hypothesis that transferrin receptorconjugated drugs can penetrate the BRB. G. Puras developed a novel niosome formulation utilizing the cationic lipid 2,3di(tetradecyloxy)propan-1-amine in combination with squalene and polysorbate 80 (Puras et al., 2014). The lipoplexes, prepared at a 15:1 ratio (cationic lipid/DNA), displayed a zeta potential of 25 mV, a size of 200 nm, and spherical morphology, effectively protecting DNA from enzymatic degradation. These lipoplexes predominantly entered ARPE-19 cells via clathrin-mediated endocytosis, while HEK-293 cells showed a preference for caveolae-dependent entry (Puras et al., 2014). Zhang et al. successfully prepared pure and active Tat PTD-endostatin from E. coli, demonstrating anti-angiogenic activity both in vivo and in vitro (Zhang et al., 2015). In vitro experiments indicated that the uptake of Tat PTD-endostatin primarily occurred via endocytosis, with both clathrin-mediated and caveolae-mediated endocytosis contributing to its internalization. Tat PTD-endostatin administered as eye drops effectively crossed ocular barriers to reach the retina (Zhang et al., 2015). Mohamed Mashal designed a novel formulation based on the N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) cationic lipid and the polysorbate 60 non-ionic surfactant for the delivery of genetic material into the retina (Mashal et al., 2017). Niosomes containing lycopene exhibited a positive zeta potential, nanometric size, and low polydispersity, successfully transfecting the outer segments of the rat retina following subretinal or intravitreal administration. In vitro assays indicated that caveolae-mediated endocytosis and micropinocytosis were the likely internalization pathways for these niosomes (Mashal et al., 2017). Additionally, niosomes formulated with squalene as a helper lipid demonstrated high transfection efficiency in ARPE-19 cells, largely due to significant cellular uptake and the utilization of specific entry pathways, particularly macropinocytosis and lysosomal escape mechanisms (Ojeda et al., 2016). Stearylated (STR)-CH2R4H2C (CH2R4), a cytoplasmresponsive STR peptide, facilitates stable siRNA complexation, enhances cell permeation, and enables the control of intracellular dynamics. The cationic amino acids, particularly arginine, in CH2R4 promote cellular uptake via macropinocytosis by activating cytoskeletal F-actin, while its cysteine residue contributes to siRNA release (Nishida et al., 2023). Li et al. developed micellar dasatinib that encapsulated dasatinib into nanoparticles prepared from micellation of PEG-b-PCL. Micellar dasatinib significantly suppressed cell adhesion, migration, and proliferation compared to free dasatinib, likely due to enhanced solubility (Li et al., 2016). In vitro assays

indicated that micellar dasatinib entered ARPE-19 cells via both caveolae-mediated and clathrin-mediated endocytosis. Furthermore, human serum albumin nanoparticles (HSA NPs) demonstrate significant potential as gene delivery vectors for effective gene therapy applications, with cellular uptake mediated by both clathrindependent and caveolae-dependent endocytosis (Mo et al., 2007). Current advancements in adeno-associated virus (AAV)-based gene therapy have demonstrated robust clinical and preclinical success for inherited retinal diseases. The AAV serotypes 1, 2, 4, 5, 7, 8, and 9 exhibit efficient transduction of RPE cells, while photoreceptor transduction efficacy varies significantly across serotypes. Notably, chimeric variants AAV2/5, 2/7, 2/8, and 2/9 show superior photoreceptor-targeting capabilities. However, the mechanisms underlying vector traversal across the BRB remain unclear. Ding et al. revealed that AAV2 traverse RPE cells via transcytosis to reach photoreceptors following suprachoroidal administration. This transport process subjected the vectors to proteasomal degradation, inhibition of which significantly enhanced photoreceptor transduction efficiency (Ding et al., 2021). Recently, Wang et al. developed a vascular cell adhesion molecule 1 (VCAM1)-targeted ultrasound-activated liposomal system capable of recognizing VCAM1 on vascular endothelial cells, initiating receptor-mediated transcytosis to achieve transendothelial transport towards biofilm-associated surgical site infection areas. However, the feasibility of this approach for penetrating the BRB requires further experimental validation (Wang et al., 2025).

Mfsd2a is a promising target for drug delivery across the BRB. Two primary Mfsd2a-based strategies exist for facilitating the transport of drugs from the blood to the retina (Wang et al., 2016). First, the reversible suppression of Mfsd2a may lead to a temporary increase in transcytosis in retinal vascular endothelial cells, thereby enhancing the transport of macromolecular drugs across the BRB. Previous evidence indicates that Mfsd2a mediates the transport of tunicamycin across cellular barriers (Reiling et al., 2011). Notably, Ben-Zvi et al. proposed tunicamycin and its structural derivatives as potential Mfsd2a inhibitors, and Wang et al. hypothesized that tunicamycinmediated suppression of Mfsd2a may be reversible, because transient binding occurs during active transport followed by subsequent dissociation within the central nervous system microenvironment (Wang et al., 2016). Further investigations are needed to optimize Mfsd2a inhibitor design through structural and functional characterization. Second, Mfsd2a can function as a transport mechanism for specific small-molecule drugs that are chemically conjugated to LPC for delivery across the BRB. Future research should focus on improving tissue specificity and drug uptake efficiency to enhance the effectiveness of transcytosis-mediated drug delivery systems.

7 Conclusion

Retinal endothelial transcytosis is a crucial process for transporting macromolecules from the vascular compartment into surrounding tissues. While the role of transcytosis in the development of the BRB and in diseases associated with BRB breakdown has been preliminarily studied, several significant unresolved issues warrant further investigation. For instance, the real-time dynamics of transcytosis in the retina remain unclear. Developing new methods to visualize and assess the dynamics of endothelial transcytosis *in vivo* is essential for understanding the directionality and speed of vesicular trafficking. Additionally, it is important to explore whether mechanisms beyond caveolae-mediated transcytosis, clathrin-mediated transcytosis, and micropinocytosis regulate this process. Furthermore, the neurovascular unit comprises various cell types and structures that collaborate to maintain retina homeostasis. It remains unclear whether the crosstalk between endothelial cells and other cell types affects endothelial transcytosis. Finally, significant challenges persist in developing efficient and specific drug delivery systems based on transcytosis. A comprehensive understanding of BRB transport, protein engineering, and pharmacokinetics is essential for improving the clinical applicability of transcytosis-mediated drug delivery systems.

Author contributions

C-LZ: Conceptualization, Investigation, Writing – original draft. J-JM: Visualization, Writing – original draft. XL: Visualization, Writing – original draft. H-QY: Writing – review and editing. Y-KG: Writing – review and editing. Z-XY: Writing – review and editing. M-FY: Conceptualization, Writing – review and editing. PZ: Conceptualization, Funding acquisition, Supervision, Writing – review and editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by 2019 Joint Construction Project of Henan Provincial Health Committee and Ministry of Health (Grant No. SB201901061), Henan Key Laboratory of Neurorestoratology (Grant No. HNSJXF-2021-004), and Postgraduate Education Reform and Quality Improvement Project of Henan Province (Grant No. YJS2021AL063).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Ajikumar, A., Long, M. B., Heath, P. R., Wharton, S. B., Ince, P. G., Ridger, V. C., et al. (2019). Neutrophil-derived microvesicle induced dysfunction of brain microvascular endothelial cells *in vitro*. *Int. J. Mol. Sci.* 20 (20), 5227. doi:10.3390/ijms20205227

Alam, P., Holst, M. R., Lauritsen, L., Nielsen, J., Nielsen, S. S. E., Jensen, P. H., et al. (2022). Polarized α -synuclein trafficking and transcytosis across brain endothelial cells via Rab7-decorated carriers. *Fluids Barriers CNS* 19 (1), 37. doi:10.1186/s12987-022-00334-y

Anderson, R. G. (2008). Transendothelial movement and caveolae. Nat. Biotechnol. 26 (4), 380–382. author reply 381-382. doi:10.1038/nbt0408-380

Andreone, B. J., Chow, B. W., Tata, A., Lacoste, B., Ben-Zvi, A., Bullock, K., et al. (2017). Blood-brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis. *Neuron* 94 (3), 581–594.e5. doi:10.1016/j.neuron.2017.03.043

Asasutjarit, R., Managit, C., Phanaksri, T., Treesuppharat, W., and Fuongfuchat, A. (2020). Formulation development and *in vitro* evaluation of transferrin-conjugated liposomes as a carrier of ganciclovir targeting the retina. *Int. J. Pharm.* 577, 119084. doi:10.1016/j.ijpharm.2020.119084

Atkinson, E. G., Jones, S., Ellis, B. A., Dumonde, D. C., and Graham, E. (1991). Molecular size of retinal vascular leakage determined by FITC-dextran angiography in patients with posterior uveitis. *Eye (Lond)* 5 (Pt 4), 440–446. doi:10.1038/eye.1991.71

Bendayan, M., and Rasio, E. A. (1996). Transport of insulin and albumin by the microvascular endothelium of the rete mirabile. *J. Cell Sci.* 109 (Pt 7), 1857–1864. doi:10. 1242/ics.109.7.1857

Ben-Zvi, A., Lacoste, B., Kur, E., Andreone, B. J., Mayshar, Y., Yan, H., et al. (2014). Mfsd2a is critical for the formation and function of the blood-brain barrier. *Nature* 509 (7501), 507–511. doi:10.1038/nature13324

Bernier-Latmani, J., Cisarovsky, C., Demir, C. S., Bruand, M., Jaquet, M., Davanture, S., et al. (2015). DLL4 promotes continuous adult intestinal lacteal regeneration and dietary fat transport. J. Clin. Invest. 125 (12), 4572–4586. doi:10.1172/jci82045

Bodor, C., Nagy, J. P., Végh, B., Németh, A., Jenei, A., MirzaHosseini, S., et al. (2012). Angiotensin II increases the permeability and PV-1 expression of endothelial cells. *Am. J. Physiol. Cell Physiol.* 302 (1), C267–C276. doi:10.1152/ajpcell.00138.2011

Boopathy, G. T. K., Kulkarni, M., Ho, S. Y., Boey, A., Chua, E. W. M., Barathi, V. A., et al. (2017). Cavin-2 regulates the activity and stability of endothelial nitric-oxide synthase (eNOS) in angiogenesis. *J. Biol. Chem.* 292 (43), 17760–17776. doi:10.1074/jbc. M117.794743

Bora, K., Wang, Z., Yemanyi, F., Maurya, M., Blomfield, A. K., Tomita, Y., et al. (2022). Endothelial cell transcytosis assay as an *in vitro* model to evaluate inner blood-retinal barrier permeability. *J. Vis. Exp.* 184. doi:10.3791/64076

Busija, A. R., Patel, H. H., and Insel, P. A. (2017). Caveolins and cavins in the trafficking, maturation, and degradation of caveolae: implications for cell physiology. *Am. J. Physiol. Cell Physiol.* 312 (4), C459-c477. doi:10.1152/ajpcell.00355.2016

Campbell, M., and Humphries, P. (2012). The blood-retina barrier: tight junctions and barrier modulation. *Adv. Exp. Med. Biol.* 763, 70–84. doi:10.1007/978-1-4614-4711-5_3

Chang, S. H., Feng, D., Nagy, J. A., Sciuto, T. E., Dvorak, A. M., and Dvorak, H. F. (2009). Vascular permeability and pathological angiogenesis in caveolin-1-null mice. *Am. J. Pathol.* 175 (4), 1768–1776. doi:10.2353/ajpath.2009.090171

Chettimada, S., Yang, J., Moon, H. G., and Jin, Y. (2015). Caveolae, caveolin-1 and cavin-1: emerging roles in pulmonary hypertension. *World J. Respirol.* 5 (2), 126–134. doi:10.5320/wjr.v5.i2.126

Chow, B. W., and Gu, C. (2017). Gradual suppression of transcytosis governs functional blood-retinal barrier formation. *Neuron* 93 (6), 1325–1333.e3. doi:10. 1016/j.neuron.2017.02.043

Comin, C. H., Tsirukis, D. I., Sun, Y., and Xu, X. (2021). Quantification of retinal blood leakage in fundus fluorescein angiography in a retinal angiogenesis model. *Sci. Rep.* 11 (1), 19903. doi:10.1038/s41598-021-99434-2

Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., et al. (2013). Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. *Nature* 497 (7451), 633–637. doi:10.1038/nature12138

Cui, Y., Wang, Y., Song, X., Ning, H., Zhang, Y., Teng, Y., et al. (2021). Brain endothelial PTEN/AKT/NEDD4-2/MFSD2A axis regulates blood-brain barrier permeability. *Cell Rep.* 36 (1), 109327. doi:10.1016/j.celrep.2021.109327

Cunha-Vaz, J., Bernardes, R., and Lobo, C. (2011). Blood-retinal barrier. Eur. J. Ophthalmol. 21 (Suppl. 6), S3–S9. doi:10.5301/ejo.2010.6049

Daneman, R., Zhou, L., Kebede, A. A., and Barres, B. A. (2010). Pericytes are required for blood-brain barrier integrity during embryogenesis. *Nature* 468 (7323), 562–566. doi:10.1038/nature09513

Deane, R., Sagare, A., Hamm, K., Parisi, M., LaRue, B., Guo, H., et al. (2005). IgGassisted age-dependent clearance of Alzheimer's amyloid beta peptide by the bloodbrain barrier neonatal Fc receptor. *J. Neurosci.* 25 (50), 11495–11503. doi:10.1523/ jneurosci.3697-05.2005 Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., et al. (2004). LRP/ amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. *Neuron* 43 (3), 333–344. doi:10.1016/j.neuron.2004.07.017

Deffebach, M. E., Bryan, C. J., and Hoy, C. M. (1996). Protein movement across cultured Guinea pig trachea: specificity and effect of transcytosis inhibitors. *Am. J. Physiol.* 271 (5 Pt 1), L744–L752. doi:10.1152/ajplung.1996.271.5.L744

DiLucia, S. G., Kendrick, B. J., and Sims-Robinson, C. (2023). Hyperinsulinemia impairs clathrin-mediated endocytosis of the insulin receptor and activation of endothelial nitric oxide synthase in brain endothelial cells. *Int. J. Mol. Sci.* 24 (19), 14670. doi:10.3390/ijms241914670

Ding, K., Shen, J., Hackett, S., Khan, M., and Campochiaro, P. A. (2021). Proteosomal degradation impairs transcytosis of AAV vectors from suprachoroidal space to retina. *Gene Ther.* 28 (12), 740–747. doi:10.1038/s41434-021-00233-1

Ding, S. Y., Liu, L., and Pilch, P. F. (2017). Muscular dystrophy in PTFR/cavin-1 null mice. JCI Insight 2 (5), e91023. doi:10.1172/jci.insight.91023

Doggett, T. M., and Breslin, J. W. (2014). Acute alcohol intoxication-induced microvascular leakage. *Alcohol Clin. Exp. Res.* 38 (9), 2414–2426. doi:10.1111/acer. 12525

Duffy, K. R., and Pardridge, W. M. (1987). Blood-brain barrier transcytosis of insulin in developing rabbits. *Brain Res.* 420 (1), 32–38. doi:10.1016/0006-8993(87)90236-8

Dvorak, A. M., Kohn, S., Morgan, E. S., Fox, P., Nagy, J. A., and Dvorak, H. F. (1996). The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. *J. Leukoc. Biol.* 59 (1), 100–115. doi:10.1002/jlb.59.1.100

Eser Ocak, P., Ocak, U., Sherchan, P., Zhang, J. H., and Tang, J. (2020). Insights into major facilitator superfamily domain-containing protein-2a (Mfsd2a) in physiology and pathophysiology. What do we know so far? *J. Neurosci. Res.* 98 (1), 29–41. doi:10.1002/jnr.24327

Essner, E., Lin, W. L., and Gordon, S. (1986). Surface-associated vesicles in retinal arterioles and venules. *Cell Tissue Res.* 245 (2), 431–437. doi:10.1007/bf00213951

Farber, G., Hurtado, R., Loh, S., Monette, S., Mtui, J., Kopan, R., et al. (2018). Glomerular endothelial cell maturation depends on ADAM10, a key regulator of Notch signaling. *Angiogenesis* 21 (2), 335–347. doi:10.1007/s10456-018-9599-4

Filippini, A., Sica, G., and D'Alessio, A. (2018). The caveolar membrane system in endothelium: from cell signaling to vascular pathology. *J. Cell Biochem.* 119 (7), 5060–5071. doi:10.1002/jcb.26793

Fra, A. M., Williamson, E., Simons, K., and Parton, R. G. (1995). *De novo* formation of caveolae in lymphocytes by expression of VIP21-caveolin. *Proc. Natl. Acad. Sci. U. S. A.* 92 (19), 8655–8659. doi:10.1073/pnas.92.19.8655

Fujimoto, T., Kogo, H., Nomura, R., and Une, T. (2000). Isoforms of caveolin-1 and caveolar structure. J. Cell Sci. 113 Pt 19, 3509–3517. doi:10.1242/jcs.113.19.3509

Fung, K. Y. Y., Fairn, G. D., and Lee, W. L. (2018). Transcellular vesicular transport in epithelial and endothelial cells: challenges and opportunities. *Traffic* 19 (1), 5–18. doi:10. 1111/tra.12533

Garcia-Castillo, M. D., Chinnapen, D. J., and Lencer, W. I. (2017). Membrane transport across polarized epithelia. *Cold Spring Harb. Perspect. Biol.* 9 (9), a027912. doi:10.1101/cshperspect.a027912

Gelfand, M. V., Hagan, N., Tata, A., Oh, W. J., Lacoste, B., Kang, K. T., et al. (2014). Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding. *Elife* 3, e03720. doi:10.7554/eLife.03720

Ghitescu, L., Fixman, A., Simionescu, M., and Simionescu, N. (1986). Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: receptor-mediated transcytosis. *J. Cell Biol.* 102 (4), 1304–1311. doi:10. 1083/jcb.102.4.1304

Gokani, S., and Bhatt, L. K. (2022). Caveolin-1: a promising therapeutic target for diverse diseases. *Curr. Mol. Pharmacol.* 15 (5), 701–715. doi:10.2174/1874467214666211130155902

Greene, C., and Campbell, M. (2016). Tight junction modulation of the blood brain barrier: CNS delivery of small molecules. *Tissue Barriers* 4 (1), e1138017. doi:10.1080/21688370.2015.1138017

Hansen, C. G., Bright, N. A., Howard, G., and Nichols, B. J. (2009). SDPR induces membrane curvature and functions in the formation of caveolae. *Nat. Cell Biol.* 11 (7), 807–814. doi:10.1038/ncb1887

Hansen, C. G., Shvets, E., Howard, G., Riento, K., and Nichols, B. J. (2013). Deletion of cavin genes reveals tissue-specific mechanisms for morphogenesis of endothelial caveolae. *Nat. Commun.* 4, 1831. doi:10.1038/ncomms2808

Hawkins, R. A., O'Kane, R. L., Simpson, I. A., and Viña, J. R. (2006). Structure of the blood-brain barrier and its role in the transport of amino acids. *J. Nutr.* 136 (1 Suppl. l), 218s–226s. doi:10.1093/jn/136.1.218S

Hellström, M., Phng, L. K., Hofmann, J. J., Wallgard, E., Coultas, L., Lindblom, P., et al. (2007). Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. *Nature* 445 (7129), 776–780. doi:10.1038/nature05571

Hermann, D. M., and Bassetti, C. L. (2007). Implications of ATP-binding cassette transporters for brain pharmacotherapies. *Trends Pharmacol. Sci.* 28 (3), 128–134. doi:10.1016/j.tips.2007.01.007

Herrnberger, L., Seitz, R., Kuespert, S., Bösl, M. R., Fuchshofer, R., and Tamm, E. R. (2012). Lack of endothelial diaphragms in fenestrae and caveolae of mutant Plvap-deficient mice. *Histochem Cell Biol.* 138 (5), 709–724. doi:10.1007/s00418-012-0987-3

Hill, M. M., Bastiani, M., Luetterforst, R., Kirkham, M., Kirkham, A., Nixon, S. J., et al. (2008). PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. *Cell* 132 (1), 113–124. doi:10.1016/j.cell.2007.11.042

Hirama, T., Das, R., Yang, Y., Ferguson, C., Won, A., Yip, C. M., et al. (2017). Phosphatidylserine dictates the assembly and dynamics of caveolae in the plasma membrane. *J. Biol. Chem.* 292 (34), 14292–14307. doi:10.1074/jbc.M117.791400

Hnasko, R., McFarland, M., and Ben-Jonathan, N. (2002). Distribution and characterization of plasmalemma vesicle protein-1 in rat endocrine glands. *J. Endocrinol.* 175 (3), 649–661. doi:10.1677/joe.0.1750649

Holmes, B. B., DeVos, S. L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., et al. (2013). Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. *Proc. Natl. Acad. Sci. U. S. A.* 110 (33), E3138–E3147. doi:10.1073/ pnas.1301440110

Hombrebueno, J. R., Ali, I. H., Xu, H., and Chen, M. (2015). Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the Ins2(Akita) diabetic mouse. *Sci. Rep.* 5, 18316. doi:10.1038/srep18316

Honeycutt, S. E., and O'Brien, L. L. (2021). Injection of Evans blue dye to fluorescently label and image intact vasculature. *Biotechniques* 70 (3), 181–185. doi:10.2144/btn-2020-0152

Hoop, C. L., Sivanandam, V. N., Kodali, R., Srnec, M. N., and van der Wel, P. C. (2012). Structural characterization of the caveolin scaffolding domain in association with cholesterol-rich membranes. *Biochemistry* 51 (1), 90–99. doi:10.1021/bi201356v

Huang, L., Chambliss, K. L., Gao, X., Yuhanna, I. S., Behling-Kelly, E., Bergaya, S., et al. (2019). SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis. *Nature* 569 (7757), 565–569. doi:10.1038/s41586-019-1140-4

Imakiire, A., Morimoto, H., Suzuki, H., Masuda, T., Yoden, E., Inoue, A., et al. (2023). Transferrin receptor-targeted iduronate-2-sulfatase penetrates the blood-retinal barrier and improves retinopathy in mucopolysaccharidosis II mice. *Mol. Pharm.* 20 (11), 5901–5909. doi:10.1021/acs.molpharmaceut.3c00736

Jabs, M., Rose, A. J., Lehmann, L. H., Taylor, J., Moll, I., Sijmonsma, T. P., et al. (2018). Inhibition of endothelial Notch signaling impairs fatty acid transport and leads to metabolic and vascular remodeling of the adult heart. *Circulation* 137 (24), 2592–2608. doi:10.1161/circulationaha.117.029733

Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., and Mason, D. Y. (1984). Transferrin receptor on endothelium of brain capillaries. *Nature* 312 (5990), 162–163. doi:10.1038/312162a0

Jiang, Y., Sverdlov, M. S., Toth, P. T., Huang, L. S., Du, G., Liu, Y., et al. (2016). Phosphatidic acid produced by RalA-activated PLD2 stimulates caveolae-mediated endocytosis and trafficking in endothelial cells. *J. Biol. Chem.* 291 (39), 20729–20738. doi:10.1074/jbc.M116.752485

Jovanović Macura, I., Djuricić, I., Major, T., Milanović, D., Brkić, M. P., Sobajic, S., et al. (2022). The high-dose fish oil supplementation increased Mfsd2a expression without altering DHA levels in the retina of healthy mice.

Jovanovic Macura, I., Milanovic, D., Tesic, V., Major, T., Perovic, M., Adzic, M., et al. (2024). The impact of high-dose fish oil supplementation on Mfsd2a, Aqp4, and amyloid- β expression in retinal blood vessels of 5xFAD alzheimer's mouse model. *Int. J. Mol. Sci.* 25 (17), 9400. doi:10.3390/ijms25179400

Kaksonen, M., and Roux, A. (2018). Mechanisms of clathrin-mediated endocytosis. *Nat. Rev. Mol. Cell Biol.* 19 (5), 313–326. doi:10.1038/nrm.2017.132

Keuschnigg, J., Tvorogov, D., Elima, K., Salmi, M., Alitalo, K., Salminen, T., et al. (2012). PV-1 is recognized by the PAL-E antibody and forms complexes with NRP-1. *Blood* 120 (1), 232–235. doi:10.1182/blood-2012-01-406876

Kim, B., Li, J., Jang, C., and Arany, Z. (2017). Glutamine fuels proliferation but not migration of endothelial cells. *Embo J*. 36 (16), 2321–2333. doi:10.15252/embj.201796436

Klaassen, I., Van Noorden, C. J., and Schlingemann, R. O. (2013). Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. *Prog. Retin Eye Res.* 34, 19–48. doi:10.1016/j.preteyeres.2013.02.001

Knowland, D., Arac, A., Sekiguchi, K. J., Hsu, M., Lutz, S. E., Perrino, J., et al. (2014). Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke. *Neuron* 82 (3), 603–617. doi:10.1016/j.neuron.2014.03.003

Kogo, H., Aiba, T., and Fujimoto, T. (2004). Cell type-specific occurrence of caveolinlalpha and -1beta in the lung caused by expression of distinct mRNAs. J. Biol. Chem. 279 (24), 25574–25581. doi:10.1074/jbc.M310807200

Krishna, A., and Sengupta, D. (2019). Interplay between membrane curvature and cholesterol: role of palmitoylated caveolin-1. *Biophys. J.* 116 (1), 69–78. doi:10.1016/j.bpj.2018.11.3127

Labrecque, L., Royal, I., Surprenant, D. S., Patterson, C., Gingras, D., and Béliveau, R. (2003). Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-

1 and plasma membrane cholesterol. *Mol. Biol. Cell* 14 (1), 334–347. doi:10.1091/mbc. e02-07-0379

Lajoie, P., and Nabi, I. R. (2010). Lipid rafts, caveolae, and their endocytosis. Int. Rev. Cell Mol. Biol. 282, 135–163. doi:10.1016/s1937-6448(10)82003-9

Lee, W. L., and Klip, A. (2016). Endothelial transcytosis of insulin: does it contribute to insulin resistance? *Physiol. (Bethesda)* 31 (5), 336–345. doi:10.1152/physiol.00010.2016

Li, Q., Lai, K. L., Chan, P. S., Leung, S. C., Li, H. Y., Fang, Y., et al. (2016). Micellar delivery of dasatinib for the inhibition of pathologic cellular processes of the retinal pigment epithelium. *Colloids Surf. B Biointerfaces* 140, 278–286. doi:10.1016/j.colsurfb.2015.12.053

Li, W., Yang, X., Zheng, T., Xing, S., Wu, Y., Bian, F., et al. (2017). TNF-α stimulates endothelial palmitic acid transcytosis and promotes insulin resistance. *Sci. Rep.* 7, 44659. doi:10.1038/srep44659

Li, Y. N., Liang, H. W., Zhang, C. L., Qiu, Y. M., Wang, D., Wang, H. L., et al. (2023). Ophthalmic solution of smart supramolecular peptides to capture semaphorin 4D against diabetic retinopathy. *Adv. Sci. (Weinh)* 10 (3), e2203351. doi:10.1002/advs.202203351

Liebner, S., Corada, M., Bangsow, T., Babbage, J., Taddei, A., Czupalla, C. J., et al. (2008). Wnt/beta-catenin signaling controls development of the blood-brain barrier. *J. Cell Biol.* 183 (3), 409–417. doi:10.1083/jcb.200806024

Liebner, S., and Plate, K. H. (2010). Differentiation of the brain vasculature: the answer came blowing by the Wnt. J. Angiogenes Res. 2, 1. doi:10.1186/2040-2384-2-1

Lim, J. P., and Gleeson, P. A. (2011). Macropinocytosis: an endocytic pathway for internalising large gulps. *Immunol. Cell Biol.* 89 (8), 836–843. doi:10.1038/icb.2011.20

Lim, J. P., Gosavi, P., Mintern, J. D., Ross, E. M., and Gleeson, P. A. (2015). Sorting nexin 5 selectively regulates dorsal-ruffle-mediated macropinocytosis in primary macrophages. *J. Cell Sci.* 128 (23), 4407–4419. doi:10.1242/jcs.174359

Lin, Z. X., Yang, L. J., Huang, Q., Lin, J. H., Ren, J., Chen, Z. B., et al. (2008). Inhibition of tumor-induced edema by antisense VEGF is mediated by suppressive vesiculo-vacuolar organelles (VVO) formation. *Cancer Sci.* 99 (12), 2540–2546. doi:10.1111/j. 1349-7006.2008.00974.x

Liu, L., Brown, D., McKee, M., Lebrasseur, N. K., Yang, D., Albrecht, K. H., et al. (2008). Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. *Cell Metab.* 8 (4), 310–317. doi:10.1016/j.cmet.2008.07.008

Liu, L., Hansen, C. G., Honeyman, B. J., Nichols, B. J., and Pilch, P. F. (2014). Cavin-3 knockout mice show that cavin-3 is not essential for caveolae formation, for maintenance of body composition, or for glucose tolerance. *PLoS One* 9 (7), e102935. doi:10.1371/journal.pone.0102935

Liu, L., and Pilch, P. F. (2008). A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. *J. Biol. Chem.* 283 (7), 4314–4322. doi:10.1074/jbc.M707890200

Liu, N. Q., Lossinsky, A. S., Popik, W., Li, X., Gujuluva, C., Kriederman, B., et al. (2002). Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. *J. Virol.* 76 (13), 6689–6700. doi:10.1128/jvi.76.13.6689-6700.2002

Loh, L. N., McCarthy, E. M. C., Narang, P., Khan, N. A., and Ward, T. H. (2017). *Escherichia coli* K1 utilizes host macropinocytic pathways for invasion of brain microvascular endothelial cells. *Traffic* 18 (11), 733–746. doi:10.1111/tra.12508

Ludwig, A., Howard, G., Mendoza-Topaz, C., Deerinck, T., Mackey, M., Sandin, S., et al. (2013). Molecular composition and ultrastructure of the caveolar coat complex. *PLoS Biol.* 11 (8), e1001640. doi:10.1371/journal.pbio.1001640

Marsboom, G., Chen, Z., Yuan, Y., Zhang, Y., Tiruppathi, C., Loyd, J. E., et al. (2017). Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension. *Mol. Biol. Cell* 28 (9), 1177–1185. doi:10. 1091/mbc.E16-11-0790

Mashal, M., Attia, N., Puras, G., Martínez-Navarrete, G., Fernández, E., and Pedraz, J. L. (2017). Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60. *J. Control Release* 254, 55–64. doi:10. 1016/j.jconrel.2017.03.386

Mayor, S., and Pagano, R. E. (2007). Pathways of clathrin-independent endocytosis. *Nat. Rev. Mol. Cell Biol.* 8 (8), 603–612. doi:10.1038/nrm2216

Mazzoni, J., Smith, J. R., Shahriar, S., Cutforth, T., Ceja, B., and Agalliu, D. (2017). The Wnt inhibitor Apcdd1 coordinates vascular remodeling and barrier maturation of retinal blood vessels. *Neuron* 96 (5), 1055–1069.e6. doi:10.1016/j.neuron.2017.10.025

Mehta, D., and Malik, A. B. (2006). Signaling mechanisms regulating endothelial permeability. *Physiol. Rev.* 86 (1), 279–367. doi:10.1152/physrev.00012.2005

Méresse, S., Delbart, C., Fruchart, J. C., and Cecchelli, R. (1989). Low-density lipoprotein receptor on endothelium of brain capillaries. *J. Neurochem.* 53 (2), 340–345. doi:10.1111/j.1471-4159.1989.tb07340.x

Mo, Y., Barnett, M. E., Takemoto, D., Davidson, H., and Kompella, U. B. (2007). Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. *Mol. Vis.* 13, 746–757.

Motley, A., Bright, N. A., Seaman, M. N., and Robinson, M. S. (2003). Clathrinmediated endocytosis in AP-2-depleted cells. *J. Cell Biol.* 162 (5), 909–918. doi:10.1083/ jcb.200305145 Murata, T., Lin, M. I., Huang, Y., Yu, J., Bauer, P. M., Giordano, F. J., et al. (2007). Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. *J. Exp. Med.* 204 (10), 2373–2382. doi:10. 1084/jem.20062340

Nakagami, Y., Hatano, E., Chayama, Y., and Inoue, T. (2019). An anti-PLVAP antibody suppresses laser-induced choroidal neovascularization in monkeys. *Eur. J. Pharmacol.* 854, 240–246. doi:10.1016/j.ejphar.2019.04.035

Natarajan, R., Northrop, N., and Yamamoto, B. (2017). Fluorescein isothiocyanate (FITC)-Dextran extravasation as a measure of blood-brain barrier permeability. *Curr. Protoc. Neurosci.* 79 (9.58), 9.58.1–9.58.15. doi:10.1002/cpns.25

Nishida, S., Takashima, Y., Endo, K., and Ishihara, H. (2023). Functional peptidemodified liposomes for siRNA delivery to rat retinal pigment epithelium cells: effect of peptide sequences. *Biol. Pharm. Bull.* 46 (10), 1468–1478. doi:10.1248/bpb.b23-00081

Nistor, A., and Simionescu, M. (1986). Uptake of low density lipoproteins by the hamster lung. Interactions with capillary endothelium. *Am. Rev. Respir. Dis.* 134 (6), 1266–1272. doi:10.1164/arrd.1986.134.6.1266

O'Brown, N. M., Megason, S. G., and Gu, C. (2019). Suppression of transcytosis regulates zebrafish blood-brain barrier function. *Elife* 8, e47326. doi:10.7554/eLife.47326

O'Donnell, M. E., Lam, T. I., Tran, L. Q., Foroutan, S., and Anderson, S. E. (2006). Estradiol reduces activity of the blood-brain barrier Na-K-Cl cotransporter and decreases edema formation in permanent middle cerebral artery occlusion. J. Cereb. Blood Flow. Metab. 26 (10), 1234–1249. doi:10.1038/sj.jcbfm.9600278

Ogata, T., Naito, D., Nakanishi, N., Hayashi, Y. K., Taniguchi, T., Miyagawa, K., et al. (2014). MURC/Cavin-4 facilitates recruitment of ERK to caveolae and concentric cardiac hypertrophy induced by α 1-adrenergic receptors. *Proc. Natl. Acad. Sci. U. S.* A. 111 (10), 3811–3816. doi:10.1073/pnas.1315359111

Oh, P., Borgström, P., Witkiewicz, H., Li, Y., Borgström, B. J., Chrastina, A., et al. (2007). Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. *Nat. Biotechnol.* 25 (3), 327–337. doi:10. 1038/nbt1292

Ohtsuki, S., and Terasaki, T. (2007). Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. *Pharm. Res.* 24 (9), 1745–1758. doi:10.1007/s11095-007-9374-5

Ojeda, E., Puras, G., Agirre, M., Zarate, J., Grijalvo, S., Eritja, R., et al. (2016). The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. *Int. J. Pharm.* 503 (1-2), 115–126. doi:10.1016/j.ijpharm.2016.02.043

Palade, G. (1953). Fine structure of blood capillaries. 24(11), 1424-1424.

Pardridge, W. M., and Boado, R. J. (1991). Enhanced cellular uptake of biotinylated antisense oligonucleotide or peptide mediated by avidin, a cationic protein. *FEBS Lett.* 288 (1-2), 30–32. doi:10.1016/0014-5793(91)80996-g

Pardridge, W. M., Triguero, D., and Buciak, J. (1989). Transport of histone through the blood-brain barrier. *J. Pharmacol. Exp. Ther.* 251 (3), 821–826. doi:10.1016/s0022-3565(25)21084-9

Parton, R. G. (2018). Caveolae: structure, function, and relationship to disease. Annu. Rev. Cell Dev. Biol. 34, 111–136. doi:10.1146/annurev-cellbio-100617-062737

Pearse, B. M. (1976). Clathrin: a unique protein associated with intracellular transfer of membrane by coated vesicles. *Proc. Natl. Acad. Sci. U. S. A.* 73 (4), 1255–1259. doi:10. 1073/pnas.73.4.1255

Peng, S., Rahner, C., and Rizzolo, L. J. (2003). Apical and basal regulation of the permeability of the retinal pigment epithelium. *Invest. Ophthalmol. Vis. Sci.* 44 (2), 808–817. doi:10.1167/iovs.02-0473

Peters, K. R., Carley, W. W., and Palade, G. E. (1985). Endothelial plasmalemmal vesicles have a characteristic striped bipolar surface structure. *J. Cell Biol.* 101 (6), 2233–2238. doi:10.1083/jcb.101.6.2233

Pietra, G. G., and Johns, L. W. (1996). Confocal- and electron-microscopic localization of FITC-albumin in H2O2-induced pulmonary edema. *J. Appl. Physiol.* 80 (1), 182–190. doi:10.1152/jappl.1996.80.1.182

Pilch, P. F., and Liu, L. (2011). Fat caves: caveolae, lipid trafficking and lipid metabolism in adipocytes. *Trends Endocrinol. Metab.* 22 (8), 318–324. doi:10.1016/j. tem.2011.04.001

Pitulescu, M. E., Schmidt, I., Giaimo, B. D., Antoine, T., Berkenfeld, F., Ferrante, F., et al. (2017). Dll4 and Notch signalling couples sprouting angiogenesis and artery formation. *Nat. Cell Biol.* 19 (8), 915–927. doi:10.1038/ncb3555

Platania, C. B. M., Lazzara, F., Mitton, K., Haque, N., Dailey, W., Conti, F., et al. (2025). Blockade of P2X7 receptors preserves blood retinal barrier integrity by modulating the plasmalemma vesicle-associated protein: implications for diabetic retinopathy. *Br. J. Pharmacol.* doi:10.1111/bph.70007

Predescu, D., Vogel, S. M., and Malik, A. B. (2004). Functional and morphological studies of protein transcytosis in continuous endothelia. *Am. J. Physiol. Lung Cell Mol. Physiol.* 287 (5), L895–L901. doi:10.1152/ajplung.00075.2004

Puddu, A., Montecucco, F., and Maggi, D. (2023). Caveolin-1 and atherosclerosis: regulation of LDLs fate in endothelial cells. *Int. J. Mol. Sci.* 24 (10), 8869. doi:10.3390/ ijms24108869

Pulgar, V. M. (2018). Transcytosis to cross the blood brain barrier, new advancements and challenges. *Front. Neurosci.* 12, 1019. doi:10.3389/fnins.2018.01019

Puras, G., Mashal, M., Zárate, J., Agirre, M., Ojeda, E., Grijalvo, S., et al. (2014). A novel cationic niosome formulation for gene delivery to the retina. *J. Control Release* 174, 27–36. doi:10.1016/j.jconrel.2013.11.004

Raghu, H., Sharma-Walia, N., Veettil, M. V., Sadagopan, S., and Chandran, B. (2009). Kaposi's sarcoma-associated herpesvirus utilizes an actin polymerizationdependent macropinocytic pathway to enter human dermal microvascular endothelial and human umbilical vein endothelial cells. *J. Virol.* 83 (10), 4895–4911. doi:10.1128/jvi.02498-08

Raheel, H., Ghaffari, S., Khosraviani, N., Mintsopoulos, V., Auyeung, D., Wang, C., et al. (2019). CD36 mediates albumin transcytosis by dermal but not lung microvascular endothelial cells: role in fatty acid delivery. Am. J. Physiol. Lung Cell Mol. Physiol. 316 (5), L740–I750. doi:10.1152/ajplung.00127.2018

Razani, B., Engelman, J. A., Wang, X. B., Schubert, W., Zhang, X. L., Marks, C. B., et al. (2001). Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. *J. Biol. Chem.* 276 (41), 38121–38138. doi:10.1074/jbc. M105408200

Razani, B., Wang, X. B., Engelman, J. A., Battista, M., Lagaud, G., Zhang, X. L., et al. (2002). Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. *Mol. Cell Biol.* 22 (7), 2329–2344. doi:10.1128/mcb.22.7. 2329-2344.2002

Reiling, J. H., Clish, C. B., Carette, J. E., Varadarajan, M., Brummelkamp, T. R., and Sabatini, D. M. (2011). A haploid genetic screen identifies the major facilitator domain containing 2A (MFSD2A) transporter as a key mediator in the response to tunicamycin. *Proc. Natl. Acad. Sci. U. S. A.* 108 (29), 11756–11765. doi:10.1073/pnas.1018098108

Richter, T., Floetenmeyer, M., Ferguson, C., Galea, J., Goh, J., Lindsay, M. R., et al. (2008). High-resolution 3D quantitative analysis of caveolar ultrastructure and caveolacytoskeleton interactions. *Traffic* 9 (6), 893–909. doi:10.1111/j.1600-0854.2008.00733.x

Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., and Hall, A. (1992). The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. *Cell* 70 (3), 401–410. doi:10.1016/0092-8674(92)90164-8

Roberts, R. L., Fine, R. E., and Sandra, A. (1993). Receptor-mediated endocytosis of transferrin at the blood-brain barrier. *J. Cell Sci.* 104 (Pt 2), 521–532. doi:10.1242/jcs. 104.2.521

Rothberg, K. G., Heuser, J. E., Donzell, W. C., Ying, Y. S., Glenney, J. R., and Anderson, R. G. (1992). Caveolin, a protein component of caveolae membrane coats. *Cell* 68 (4), 673–682. doi:10.1016/0092-8674(92)90143-z

Sade, H., Baumgartner, C., Hugenmatter, A., Moessner, E., Freskgård, P. O., and Niewoehner, J. (2014). A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding. *PLoS One* 9 (4), e96340. doi:10.1371/journal.pone.0096340

Sadeghian, H., Lacoste, B., Qin, T., Toussay, X., Rosa, R., Oka, F., et al. (2018). Spreading depolarizations trigger caveolin-1-dependent endothelial transcytosis. *Ann. Neurol.* 84 (3), 409–423. doi:10.1002/ana.25298

Saunders, N. R., Dziegielewska, K. M., Møllgård, K., and Habgood, M. D. (2015). Markers for blood-brain barrier integrity: how appropriate is Evans blue in the twenty-first century and what are the alternatives? *Front. Neurosci.* 9, 385. doi:10.3389/fnins.2015.00385

Schlingemann, R. O., Dingjan, G. M., Emeis, J. J., Blok, J., Warnaar, S. O., and Ruiter, D. J. (1985). Monoclonal antibody PAL-E specific for endothelium. *Lab. Invest.* 52 (1), 71–76.

Schlingemann, R. O., Hofman, P., Vrensen, G. F., and Blaauwgeers, H. G. (1999). Increased expression of endothelial antigen PAL-E in human diabetic retinopathy correlates with microvascular leakage. *Diabetologia* 42 (5), 596–602. doi:10.1007/ s001250051200

Schlossman, D. M., Schmid, S. L., Braell, W. A., and Rothman, J. E. (1984). An enzyme that removes clathrin coats: purification of an uncoating ATPase. J. Cell Biol. 99 (2), 723–733. doi:10.1083/jcb.99.2.723

Schubert, W., Frank, P. G., Razani, B., Park, D. S., Chow, C. W., and Lisanti, M. P. (2001). Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin *in vivo. J. Biol. Chem.* 276 (52), 48619–48622. doi:10.1074/jbc.C100613200

Sengupta, D. (2012). Cholesterol modulates the structure, binding modes, and energetics of caveolin-membrane interactions. *J. Phys. Chem. B* 116 (50), 14556–14564. doi:10.1021/jp3077886

Simionescu, M., Simionescu, N., and Palade, G. E. (1974). Morphometric data on the endothelium of blood capillaries. J. Cell Biol. 60 (1), 128–152. doi:10.1083/jcb.60.1.128

Singh, S. R., Grossniklaus, H. E., Kang, S. J., Edelhauser, H. F., Ambati, B. K., and Kompella, U. B. (2009). Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. *Gene Ther.* 16 (5), 645–659. doi:10.1038/gt.2008.185

Spector, R., and Johanson, C. E. (2007). Vitamin transport and homeostasis in mammalian brain: focus on Vitamins B and E. J. Neurochem. 103 (2), 425–438. doi:10. 1111/j.1471-4159.2007.04773.x

Stan, R. V. (2004). Multiple PV1 dimers reside in the same stomatal or fenestral diaphragm. *Am. J. Physiol. Heart Circ. Physiol.* 286 (4), H1347–H1353. doi:10.1152/ajpheart.00909.2003

Stan, R. V. (2005). Structure of caveolae. *Biochim. Biophys. Acta* 1746 (3), 334–348. doi:10.1016/j.bbamcr.2005.08.008

Stan, R. V. (2007). Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis. J. Cell Mol. Med. 11 (4), 621–643. doi:10.1111/j.1582-4934.2007. 00075.x

Stan, R. V., Ghitescu, L., Jacobson, B. S., and Palade, G. E. (1999). Isolation, cloning, and localization of rat PV-1, a novel endothelial caveolar protein. *J. Cell Biol.* 145 (6), 1189–1198. doi:10.1083/jcb.145.6.1189

Stan, R. V., Roberts, W. G., Predescu, D., Ihida, K., Saucan, L., Ghitescu, L., et al. (1997). Immunoisolation and partial characterization of endothelial plasmalemmal vesicles (caveolae). *Mol. Biol. Cell* 8 (4), 595–605. doi:10.1091/mbc.8.4.595

Stapleton, N. M., Brinkhaus, M., Armour, K. L., Bentlage, A. E. H., de Taeye, S. W., Temming, A. R., et al. (2019). Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge. *Sci. Rep.* 9 (1), 7363. doi:10.1038/s41598-019-40731-2

Suchting, S., Freitas, C., le Noble, F., Benedito, R., Bréant, C., Duarte, A., et al. (2007). The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. *Proc. Natl. Acad. Sci. U. S. A.* 104 (9), 3225–3230. doi:10.1073/pnas.0611177104

Sweitzer, S. M., and Hinshaw, J. E. (1998). Dynamin undergoes a GTP-dependent conformational change causing vesiculation. *Cell* 93 (6), 1021–1029. doi:10.1016/s0092-8674(00)81207-6

Tahir, S. A., Park, S., and Thompson, T. C. (2009). Caveolin-1 regulates VEGFstimulated angiogenic activities in prostate cancer and endothelial cells. *Cancer Biol. Ther.* 8 (23), 2286–2296. doi:10.4161/cbt.8.23.10138

Tajima, K., Akanuma, S. I., Ohishi, Y., Yoshida, Y., Bauer, B., Kubo, Y., et al. (2022). Freshly isolated retinal capillaries to determine efflux transporter function at the inner BRB. *J. Control Release* 343, 434–442. doi:10.1016/j.jconrel.2022.01.037

Tang, W., Li, Y., Li, Y., and Wang, Q. (2021). Caveolin-1, a novel player in cognitive decline. *Neurosci. Biobehav Rev.* 129, 95–106. doi:10.1016/j.neubiorev.2021.06.044

Taniguchi, T., Maruyama, N., Ogata, T., Kasahara, T., Nakanishi, N., Miyagawa, K., et al. (2016). PTRF/Cavin-1 deficiency causes cardiac dysfunction accompanied by cardiomyocyte hypertrophy and cardiac fibrosis. *PLoS One* 11 (9), e0162513. doi:10. 1371/journal.pone.0162513

Taylor, C. J., Nicola, P. A., Wang, S., Barrand, M. A., and Hladky, S. B. (2006). Transporters involved in regulation of intracellular pH in primary cultured rat brain endothelial cells. *J. Physiol.* 576 (Pt 3), 769–785. doi:10.1113/jphysiol.2006.117374

Thomas, G. W., Rael, L. T., Hausburg, M., Frederick, E. D., Brody, E., and Bar-Or, D. (2016). The low molecular weight fraction of commercial human serum albumin induces acetylation of α -tubulin and reduces transcytosis in retinal endothelial cells. *Biochem. Biophys. Res. Commun.* 478 (4), 1780–1785. doi:10.1016/j.bbrc.2016.09.026

Tkachenko, E., Tse, D., Sideleva, O., Deharvengt, S. J., Luciano, M. R., Xu, Y., et al. (2012). Caveolae, fenestrae and transendothelial channels retain PV1 on the surface of endothelial cells. *PLoS One* 7 (3), e32655. doi:10.1371/journal.pone.0032655

Tuma, P., and Hubbard, A. L. (2003). Transcytosis: crossing cellular barriers. *Physiol. Rev.* 83 (3), 871–932. doi:10.1152/physrev.00001.2003

Umans, R. A., Henson, H. E., Mu, F., Parupalli, C., Ju, B., Peters, J. L., et al. (2017). CNS angiogenesis and barriergenesis occur simultaneously. *Dev. Biol.* 425 (2), 101–108. doi:10.1016/j.ydbio.2017.03.017

Van Geest, R. J., Lesnik-Oberstein, S. Y., Tan, H. S., Mura, M., Goldschmeding, R., Van Noorden, C. J., et al. (2012). A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. *Br. J. Ophthalmol.* 96 (4), 587–590. doi:10. 1136/bjophthalmol-2011-301005

Vasile, E., Simionescu, M., and Simionescu, N. (1983). Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium *in situ. J. Cell Biol.* 96 (6), 1677–1689. doi:10.1083/jcb.96.6.1677

Vinten, J., Johnsen, A. H., Roepstorff, P., Harpøth, J., and Tranum-Jensen, J. (2005). Identification of a major protein on the cytosolic face of caveolae. *Biochim. Biophys. Acta* 1717 (1), 34–40. doi:10.1016/j.bbamem.2005.09.013

Vorbrodt, A. W. (1988). Ultrastructural cytochemistry of blood-brain barrier endothelia. Prog. Histochem Cytochem 18 (3), 1–99. doi:10.1016/s0079-6336(88)80001-9

Wang, G., Zhang, C., Huang, Z., Chen, J., Chen, H., Lin, T., et al. (2025). Transcytosable and ultrasound-activated liposome enables deep penetration of biofilm for surgical site infection management. *Adv. Mater* 37 (1), e2411092. doi:10.1002/adma.202411092

Wang, J. T., Teasdale, R. D., and Liebl, D. (2014). Macropinosome quantitation assay. *MethodsX* 1, 36–41. doi:10.1016/j.mex.2014.05.002

Wang, J. Z., Xiao, N., Zhang, Y. Z., Zhao, C. X., Guo, X. H., and Lu, L. M. (2016). Mfsd2a-based pharmacological strategies for drug delivery across the blood-brain barrier. *Pharmacol. Res.* 104, 124–131. doi:10.1016/j.phrs.2015.12.024 Wang, Z., Liu, C. H., Huang, S., Fu, Z., Tomita, Y., Britton, W. R., et al. (2020). Wnt signaling activates MFSD2A to suppress vascular endothelial transcytosis and maintain blood-retinal barrier. *Sci. Adv.* 6 (35), eaba7457. doi:10.1126/sciadv.aba7457

Wasserman, S. M., Mehraban, F., Komuves, L. G., Yang, R. B., Tomlinson, J. E., Zhang, Y., et al. (2002). Gene expression profile of human endothelial cells exposed to sustained fluid shear stress. *Physiol. Genomics* 12 (1), 13–23. doi:10.1152/ physiolgenomics.00102.2002

Wennström, S., Hawkins, P., Cooke, F., Hara, K., Yonezawa, K., Kasuga, M., et al. (1994). Activation of phosphoinositide 3-kinase is required for PDGF-stimulated membrane ruffling. *Curr. Biol.* 4 (5), 385–393. doi:10.1016/s0960-9822(00)00087-7

West, M. A., Bretscher, M. S., and Watts, C. (1989). Distinct endocytotic pathways in epidermal growth factor-stimulated human carcinoma A431 cells. *J. Cell Biol.* 109 (6 Pt 1), 2731–2739. doi:10.1083/jcb.109.6.2731

Wisniewska-Kruk, J., Hoeben, K. A., Vogels, I. M., Gaillard, P. J., Van Noorden, C. J., Schlingemann, R. O., et al. (2012). A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes. *Exp. Eye Res.* 96 (1), 181–190. doi:10.1016/j.exer.2011.12.003

Wisniewska-Kruk, J., Klaassen, I., Vogels, I. M., Magno, A. L., Lai, C. M., Van Noorden, C. J., et al. (2014). Molecular analysis of blood-retinal barrier loss in the Akimba mouse, a model of advanced diabetic retinopathy. *Exp. Eye Res.* 122, 123–131. doi:10.1016/j.exer.2014.03.005

Wisniewska-Kruk, J., van der Wijk, A. E., van Veen, H. A., Gorgels, T. G., Vogels, I. M., Versteeg, D., et al. (2016). Plasmalemma vesicle-associated protein has a key role in blood-retinal barrier loss. *Am. J. Pathol.* 186 (4), 1044–1054. doi:10.1016/j.ajpath.2015. 11.019

Witmer, A. N., Blaauwgeers, H. G., Weich, H. A., Alitalo, K., Vrensen, G. F., and Schlingemann, R. O. (2002). Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. *Invest. Ophthalmol. Vis. Sci.* 43 (3), 849–857.

Wong, B. H., Chan, J. P., Cazenave-Gassiot, A., Poh, R. W., Foo, J. C., Galam, D. L., et al. (2016). Mfsd2a is a transporter for the essential ω -3 fatty acid docosahexaenoic acid (DHA) in eye and is important for photoreceptor cell development. *J. Biol. Chem.* 291 (20), 10501–10514. doi:10.1074/jbc.M116.721340

Wong, B. H., and Silver, D. L. (2020). Mfsd2a: a physiologically important lysolipid transporter in the brain and eye. *Adv. Exp. Med. Biol.* 1276, 223–234. doi:10.1007/978-981-15-6082-8_14

Wu, J. H., Li, Y. N., Chen, A. Q., Hong, C. D., Zhang, C. L., Wang, H. L., et al. (2020). Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy. *EMBO Mol. Med.* 12 (2), e10154. doi:10.15252/emmm.201810154

Yang, J. M., Park, C. S., Kim, S. H., Noh, T. W., Kim, J. H., Park, S., et al. (2020). Dll4 suppresses transcytosis for arterial blood-retinal barrier homeostasis. *Circ. Res.* 126 (6), 767–783. doi:10.1161/circresaha.119.316476

Zhang, C., Simón, M., Lim, H., Tolman, N. G., Horbal, L., Juarez, F. A., et al. (2024). IOP-induced blood-retinal barrier compromise contributes to RGC death in glaucoma. *bioRxiv*, 618539. doi:10.1101/2024.10.15.618539

Zhang, C. L., Wang, H. L., Li, P. C., Hong, C. D., Chen, A. Q., Qiu, Y. M., et al. (2021). Mfsd2a overexpression alleviates vascular dysfunction in diabetic retinopathy. *Pharmacol. Res.* 171, 105755. doi:10.1016/j.phrs.2021.105755

Zhang, X., Li, Y., Cheng, Y., Tan, H., Li, Z., Qu, Y., et al. (2015). Tat PTDendostatin: a novel anti-angiogenesis protein with ocular barrier permeability via eye-drops. *Biochim. Biophys. Acta* 1850 (6), 1140–1149. doi:10.1016/j.bbagen.2015. 01.019

Zhao, Z., Sagare, A. P., Ma, Q., Halliday, M. R., Kong, P., Kisler, K., et al. (2015). Central role for PICALM in amyloid- β blood-brain barrier transcytosis and clearance. *Nat. Neurosci.* 18 (7), 978–987. doi:10.1038/nn.4025

Zhou, K., Sumigray, K. D., and Lechler, T. (2015). The Arp2/3 complex has essential roles in vesicle trafficking and transcytosis in the mammalian small intestine. *Mol. Biol. Cell* 26 (11), 1995–2004. doi:10.1091/mbc.E14-10-1481

Zhu, B., Swärd, K., Ekman, M., Uvelius, B., and Rippe, C. (2017). Cavin-3 (PRKCDBP) deficiency reduces the density of caveolae in smooth muscle. *Cell Tissue Res.* 368 (3), 591-602. doi:10.1007/s00441-017-2587-y

Zimnicka, A. M., Husain, Y. S., Shajahan, A. N., Sverdlov, M., Chaga, O., Chen, Z., et al. (2016). Src-dependent phosphorylation of caveolin-1 Tyr-14 promotes swelling and release of caveolae. *Mol. Biol. Cell* 27 (13), 2090–2106. doi:10.1091/mbc.E15-11-0756

Zlokovic, B. V. (1995). Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. *Pharm. Res.* 12 (10), 1395–1406. doi:10. 1023/a:1016254514167

Glossary

Αβ	Amyloid-beta peptide	P2X7R	Purinergic 2X7 receptor
AJs	Adherens junctions	PDGF	Platelet-derived growth factor
AMD	Age-related macular degeneration	PDR	Proliferative diabetic retinopathy
AP2	Adaptor protein 2	PI3K	Phosphatidylinositol 3-kinase
APCDD1	Adenomatosis polyposis coli downregulated 1	PICALM	Phosphatidylinositol binding clathrin-assembly protein
BBB	Blood-brain barrier	PLVAP	Plasmalemma vesicle-associated protein
BRB	Blood-retina barrier	PTRF	Polymerase transcript release factor
CH2R4	CH2R4H2C	RCECs	Retinal capillary endothelial cells
CNS	Central nervous system	RMECs	Retinal microvascular endothelial cells
Dextran-	Dextran conjugated to tetramethylrhodamine	ROP	Retinopathy of prematurity
TMR		RPEs	Retinal pigment epithelial cells
DHA	Docosahexaenoic acid	SDPR	Serum deprivation protein response
DLL4	Delta-like ligand 4	SDs	Stomatal diaphragms
DME	Diabetic macular edema	Sec22b	SEC22 Homolog B
DOTMA	N-[1-(2,3-dioleoyloxy)propyl]-N,N,N- trimethylammonium chloride	SOX17	SRY-box transcription factor 17
DR	Diabetic retinopathy	SRBC	Srd-related gene product that binds to C-kinase
E. coli K1	Escherichia coli K1	SREBP1	Sterol regulatory element-binding protein one
EPA	Eicosapentaenoic Acid	Srgp2	Slit-Robo Rho GTPase activating protein two
ERK	Extracellular regulated protein kinases	STR	Stearylated
FDs	Fenestral diaphragms	STX7	Syntaxin7
FITC	Fluorescein isothiocyanate	STZ	Streptozotocin
FITC-dextran	Fluorescein isothiocyanate-conjugated dextran	TEC	Transendothelial channels
HBMECs	Human brain microvascular endothelial cells	Tf-GCV-LPs	Transferrin-conjugated liposomes containing ganciclovir
HEK293			
	Human embryonic kidney 293 cells	TJs	Tight junctions
HIV-1	Human embryonic kidney 293 cells Human immunodeficiency virus 1	TJs VCAM1	Tight junctions vascular cell adhesion molecule one
HIV-1 HREC	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells	TJs VCAM1 VEGF	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor
HIV-1 HREC HRP	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase	TJs VCAM1 VEGF VEGFR2	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two
HIV-1 HREC HRP HSA NPs	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles	TJs VCAM1 VEGF VEGFR2 VVOs	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles
HIV-1 HREC HRP HSA NPs HSC70	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles Heat shock cognate protein 70	TJs VCAM1 VEGF VEGFR2 VVOs Wnt	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles Wingless-related integration site
HIV-1 HREC HRP HSA NPs HSC70 HUVECs	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles Heat shock cognate protein 70 Human umbilical vein endothelial cells	TJs VCAM1 VEGF VEGFR2 VVOs Wnt ZO-1	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles Wingless-related integration site Zonula occludens-1.
HIV-1 HREC HRP HSA NPs HSC70 HUVECs KSHV	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles Heat shock cognate protein 70 Human umbilical vein endothelial cells Kaposi's sarcoma-associated herpesvirus	TJs VCAM1 VEGF VEGFR2 VVOs Wnt ZO-1	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles Wingless-related integration site Zonula occludens-1.
HIV-1 HREC HRP HSA NPs HSC70 HUVECs KSHV LDLs	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles Heat shock cognate protein 70 Human umbilical vein endothelial cells Kaposi's sarcoma-associated herpesvirus Low-density lipoproteins	TJs VCAM1 VEGF VEGFR2 VVOs Wnt ZO-1	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles Wingless-related integration site Zonula occludens-1.
HIV-1 HREC HRP HSA NPs HSC70 HUVECs KSHV LDLs LPC	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles Heat shock cognate protein 70 Human umbilical vein endothelial cells Kaposi's sarcoma-associated herpesvirus Low-density lipoproteins Lysophosphatidylcholine	TJs VCAM1 VEGF VEGFR2 VVOs Wnt ZO-1	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles Wingless-related integration site Zonula occludens-1.
HIV-1 HREC HRP HSA NPs HSC70 HUVECs KSHV LDLs LPC LRP1	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles Heat shock cognate protein 70 Human umbilical vein endothelial cells Kaposi's sarcoma-associated herpesvirus Low-density lipoproteins Lysophosphatidylcholine Low-density lipoprotein receptor-related protein 1	TJs VCAM1 VEGF VEGFR2 VVOs Wnt ZO-1	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles Wingless-related integration site Zonula occludens-1.
HIV-1 HREC HRP HSA NPs HSC70 HUVECs KSHV LDLs LPC LRP1 LRP5	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles Heat shock cognate protein 70 Human umbilical vein endothelial cells Kaposi's sarcoma-associated herpesvirus Low-density lipoproteins Lysophosphatidylcholine Low-density lipoprotein receptor-related protein 1 Low-density lipoprotein receptor-related protein 5	TJs VCAM1 VEGF VEGFR2 VVOs Wnt ZO-1	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles Wingless-related integration site Zonula occludens-1.
HIV-1 HREC HRP HSA NPs HSC70 HUVECs KSHV LDLs LPC LRP1 LRP5 MAPK	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles Heat shock cognate protein 70 Human umbilical vein endothelial cells Kaposi's sarcoma-associated herpesvirus Low-density lipoproteins Lysophosphatidylcholine Low-density lipoprotein receptor-related protein 1 Low-density lipoprotein receptor-related protein 5 mitogen-activated protein kinase	TJs VCAM1 VEGF VEGFR2 VVOs Wnt ZO-1	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles Wingless-related integration site Zonula occludens-1.
HIV-1 HREC HRP HSA NPs HSC70 HUVECs KSHV LDLs LPC LRP1 LRP5 MAPK Mfsd2a	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles Heat shock cognate protein 70 Human umbilical vein endothelial cells Kaposi's sarcoma-associated herpesvirus Low-density lipoproteins Lysophosphatidylcholine Low-density lipoprotein receptor-related protein 1 Low-density lipoprotein receptor-related protein 5 mitogen-activated protein kinase Major facilitator superfamily domain containing 2a	TJs VCAM1 VEGF VEGFR2 VVOs Wnt ZO-1	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles Wingless-related integration site Zonula occludens-1.
HIV-1 HREC HRP HSA NPs HSC70 HUVECs KSHV LDLs LPC LRP1 LRP5 MAPK Mfsd2a MURC	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles Heat shock cognate protein 70 Human umbilical vein endothelial cells Kaposi's sarcoma-associated herpesvirus Low-density lipoproteins Lysophosphatidylcholine Low-density lipoprotein receptor-related protein 1 Low-density lipoprotein receptor-related protein 5 mitogen-activated protein kinase Major facilitator superfamily domain containing 2a Muscle-restricted coiled-coil protein	TJs VCAM1 VEGF VEGFR2 VVOs Wnt ZO-1	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles Wingless-related integration site Zonula occludens-1.
HIV-1 HREC HRP HSA NPs HSC70 HUVECs KSHV LDLs LPC LRP1 LRP5 MAPK Mfsd2a MURC NKCC	Human embryonic kidney 293 cells Human immunodeficiency virus 1 Human retinal endothelial cells Horseradish peroxidase Human serum albumin nanoparticles Heat shock cognate protein 70 Human umbilical vein endothelial cells Kaposi's sarcoma-associated herpesvirus Low-density lipoproteins Lysophosphatidylcholine Low-density lipoprotein receptor-related protein 1 Low-density lipoprotein receptor-related protein 5 mitogen-activated protein kinase Major facilitator superfamily domain containing 2a Muscle-restricted coiled-coil protein Sodium-potassium-two chloride (Na ⁺ -K ⁺ -2CI ⁺) cotransporter	TJs VCAM1 VEGF VEGFR2 VVOs Wnt ZO-1	Tight junctions vascular cell adhesion molecule one Vascular endothelial growth factor Vascular endothelial growth factor receptor two Vesicular-vacuolar organelles Wingless-related integration site Zonula occludens-1.

Neuropilin-1

Oxygen-induced retinopathy

NRP-1

OIR